




UPPSALA
UNIVERSITET

Department of Medical Cell Biology

ANNUAL REPORT

2015



Fastställd av Institutionsstyrelsen 2016

Department of Medical Cell Biology

ANNUAL REPORT

2015

Introduction

First, I would like to thank professor Ulf Eriksson and senior lecturer Parri Wentzel, who both retired in 2015, for the many years of great work at the department. The contributions of Ulf and Parri in both research and teaching have been highly esteemed by colleagues at the department and by many students. One permanent position as lecturer was appointed at MCB during 2015 to Martin Blixt, who is very much welcomed.

During the year of 2015 research groups at the department of MCB have obtained several new prestigious research grants. For example, investigators, such as Olof Idevall, Gunilla Westermark and Ingela Parmryd, were awarded new grants from the Swedish Research Council. New grants were also obtained from Diabetes Wellness (Mia Phillipson, Anders Tengholm), Cancerfonden (Michael Welsh), Vinnova (Evelina Vågesjö and Mia Phillipson), Hjärt-Lungfonden (Michael Hultström) and the Novo-Nordisk Foundation (Gunilla Westermark, Olof Idevall). A commissioned research grant from Astra Zeneca has been given to Peter Bergsten.

In addition, Kailash Singh received the Young Investigators Award from the Scandinavian Society for the Study of Diabetes for best Scandinavian publication in diabetes during the year. Professor Per-Ola Carlsson received the senior research award, Knud Lundbeck Award (to a researcher who has substantially contributed to the progress of diabetes research, mainly through work conducted within the Nordic area) from the same society. Nikhil Gandasi received the European Foundation for the Study of Diabetes (EFSD) / Lilly Research Fellowship and a SSMF 2 year research fellowship. Michael Hultström received an early Career Researcher Prize, at the Neural, Hormonal and Renal Interactions in Blood Pressure Control meeting in Mussoorie, India, December 2015. Marie E. Oskarsson's PhD thesis "Islet amyloid polypeptide (IAPP) in Type 2 diabetes and Alzheimer disease" has been recognized by the Swedish Society of Diabetology (SFD) as the best preclinical dissertation in 2015.

It is also noteworthy that the MCB investigators have eminently communicated their research achievements to the general public via the news media ("tredje uppdraget"). For example, Per-Ola Carlsson has been featured in TV, radio and newspapers for new treatments in type 1 diabetes, and held several public lectures on diabetes and research for the lay community. Sebastian Barg was interviewed for an article by Mike May in Bioopticsworld in 2015. Misty Marshall became a panel member at Norwescon Science Fiction conference in Seattle. Evelina Vågesjö was elected "SKAPA framtidens innovatör i Uppland", and the winner of UIC Business Lab contest in fictional innovations. During 2015 Dr. Michael Hultström lectured about heart failure for the Swedish Pensioner's Society (SPF) on three occasions arranged by the Swedish Heart-Lung Foundation with between 40 and 100 attendees per lecture. Michael Hultström has been repeatedly invited to #NephJC, a Twitter-based journal club in nephrology to discuss hypertension and acute kidney injury, the associated account @NephJC has over 3000 followers of mostly nephrologists and some kidney interested doctors of other specialities. Finally, Mia Phillipson participated in SVT's Nobel studio as a commentator of the Nobel price in medicine. Mia Phillipson and Evelina Vågesjö wrote also the article: "Ny teknologi för accelererad läkning av sår" in SårMagasinet #3, 2015.

During 2015 our teachers Per Holmfeldt and Faranak Azerbayjani have worked very hard, and successfully, to renew and develop our courses on the Programmes for Nursing and Pharmacy, respectively. Through their efforts the students now graduate from the courses at higher numbers and with more knowledge. The medical anatomy course KARL, which is headed by Mats Hjortberg, was the winner of the annual KURT contest, which means that it reached the

highest approval by the medical students. We are also happy to congratulate Monica Sandberg, who was awarded a Pedagogical Rose by the first year medical students on 2 mars 2015.

After some economical difficulties during the past 1-2 years, the economy of the department has now stabilized. This, in combination with an upcoming retirement late 2016, allows some expansion and the department initiated late 2015 recruitments of a new senior lecturer and an associate senior lecturer (BULE) position.

To further improve the quality of research and teaching of the department three new groups have been formed; one group that deals with research, one group that deals with the training of graduate students, and one group that deals the teaching of under-graduate students. These groups meet regularly and have during 2015 composed lists of goals and strategies for the department, which delineate what improvements the department strives for and how to reach these goals. The goals and strategies are now posted on the MCB web page.

The achievements of this department depend heavily on hard and inspired work performed by our teachers, technicians, researchers, post-docs and PhD-students, but also on our staff of co-heads and administrators. Peter Hansell, deputy and assistant head of the department, manages undergraduate teaching with great finesse, and Gunilla Westermarck, assistant head of the department, takes a firm responsibility for both our graduate student education, as well as safety and working environment issues. Our financial and human resource administration duties are proficiently handled by Shumin Pan and Camilla Sävmarker, and teaching administration is excellently executed by Björn Åkerblom, Lina Thorvaldson and Erik Sandin. Göran Ståhl helps us all with practical matters and Oleg Dyachok keeps our microscopes in great shape. For all this many sincere thanks, and a special thank you to the PhD students who arranged the delightful mediterranean “julgransplundrings party”.

Nils Welsh, Department Head

Uppsala 2016-05-12

List of Contents

Introduction	2
List of Contents	4
Organization	5
Scientific Reports	7
Islet vascular physiology and cell therapy	7
Islet function in childhood obesity and type 2 diabetes mellitus	12
Physiology of pancreatic islet hormone secretion	17
Cellular architecture and organelle communication	23
Mechanisms of regulated exocytosis	28
The functional organisation of the T-cell plasma membrane	30
Importance of Shb-dependent signaling for angiogenesis and hematopoiesis	33
Complications in pregnancy	36
Pathogenesis of type 1 Diabetes Mellitus	38
Role of tyrosine kinases in β -cell apoptosis and diabetes	43
Intrarenal Hyaluronan in the Regulation of Fluid Balance. Pathophysiological Relevance to Renal Damage during Diabetes and Ischemia-Reperfusion.	46
Renal Physiology	49
Gastro-intestinal protection mechanisms studied in vivo	51
Targeting leukocytes in health and disease	54
Diabetic Nephropathy and Uremic Toxins	57
Circulatory function in acute and chronic kidney injury	64
Studies of the pathophysiological mechanisms behind protein aggregation and formation of organ and cell toxic amyloid	71
You've Got Mail: Message Delivery Within and Between Cells	74
Dissertations 2015	78
Licentiate theses 2015	78
Economy	79
Undergraduate Teaching	80
Graduate Teaching	81
MD/PhD programme	81
Centres and Facilities	82
Advanced light microscopic imaging facilities	82
Other equipment	83
Prizes and awards 2015	84
E-mail address list	84

Organization

Chairman

Nils Welsh

Deputy chairman

Peter Hansell

Vice chairmen

Peter Hansell (Director of undergraduate studies)

Gunilla Westermark (Director of graduate studies)

Department board

(From mid 2014)

Peter Hansell, teacher representative

Mia Phillipson, teacher representative

Leif Jansson, teacher representative

Per-Ola Carlsson, teacher representative

Mats Hjortberg, teacher representative, deputy

Stellan Sandler, teacher representative, deputy

Anders Tengholm, teacher representative, deputy

Gunilla Westermark, teacher representative, deputy

Björn Åkerblom, representative for technical/administrative personnel

Lisbeth Sagulin, representative for technical/administrative personnel, deputy

Lisa Grapensparr, PhD student representative

Carl Johan Drott, PhD student representative, deputy

Fredrik Lyngfalk, student representative

Shumin Pan, economy administrator, adjunct

Camilla Sävmarker, personell administrator, adjunct

Professors emeriti

Erik Gylfe

Ove Nilsson

Bo Hellman

Erik Persson

Örjan Källskog

Jan Westman

Mats Wolgast

Arne Andersson

Administration

Shumin Pan
Erik Sandin
Göran Ståhl
Camilla Sävmarker
Lina Thorvaldson
Björn Åkerblom

Computers/IT

Peter Öhrt
Magnus Jansson
Tobias Holm (BMC computer department)

Technical staff

Parvin Ahooghalandari
Angelica Fasching
Antoine Giraud
Annika Jägare
My Quach
Lisbeth Sagulin
Monica Sandberg
Jan Saras

Scientific Reports

Islet vascular physiology and cell therapy

Per-Ola Carlsson, Leif Jansson

The research of the group is mainly focused on the vasculature of the pancreatic islets and its relation to islet endocrine function during normal and diabetic conditions and after transplantation. The endothelial cells, which line all blood vessels, are important not only to distribute nutrients and oxygen to the islets, but our findings show that they also produce mediators which are involved in the regulation of hormone release, cell growth and the blood perfusion through the islets. Furthermore, endothelium-derived substances are likely to modulate the pathogenesis of both type 1 and type 2 diabetes. We have in recent years identified a functional reserve of islet endocrine cells. Normally 20-25% of islets are low oxygenated and with low protein biosynthesis, but these cells may be activated upon need during increased functional demands. On the other hand, more islets become downregulated when beta-cell mass is increased. We have also observed that the most blood-perfused islets, having a higher vascular density (Fig. 1), have a superior beta-cell function, proliferation and gene expression. However, these islets are also more prone to cellular death when stressed by hypoxia or cytokines, and they are also more prone to develop amyloid deposits.




Fig 1. Two-photon confocal images of vascularity in pancreatic islets with low (A) or high (B) blood perfusion (blood perfusion identified by microsphere measurements).

Much of our research within the last years have been devoted to the adaptation of transplanted islets of Langerhans (which contain the insulin-producing beta-cells) to the implantation organ, i.e. the so-called engraftment process, and how this may be affected by different conditions in the recipients. Such transplantations are performed also in humans, but the long-term results are disappointing, probably due to impaired engraftment. Novel strategies to improve engraftment, as well as aspects to prevent cell death and regenerate beta-cells in native and transplanted islets by stem-cell stimuli are based on these findings presently tested by the research group in both experimental and clinical studies (cf. below).

Islet transplantation and beta-cell regenerative medicine (Per-Ola Carlsson)

The overall aim of the research on islet transplantation and beta-cell regenerative medicine is to develop means to intervene with the development of type 1 diabetes mellitus and find treatment strategies to restore glucose homeostasis in patients with type 1 diabetes mellitus using cell therapy. The dual role of the P.I. as experimental and clinical scientist simplifies translational approaches, and the research group is active both at the Department of Medical Cell Biology and the Department of Medical Sciences. Studies are conducted to elucidate the importance of islet endothelial, neural, stromal or their progenitor cells for beta-cell regeneration and function, and to investigate the concept of islet heterogeneity. Other studies investigate the adaptation of pancreatic islets to the implantation organ, i.e. the so called engraftment process, following transplantation (Fig. 2), and develop bioengineering strategies (coating of islets with supporting stem cells, oxygen carriers and growth factors, as well as with use of scaffolds) to improve results of pancreatic islet transplantation by enhancement of engraftment e.g. by improved revascularization. Human islets are tested in

these experimental systems with a focus to produce clinically applicable protocols. We also perform research to develop safe and effective means to generate new human beta-cells by stimulating adult beta-cell proliferation, e.g. by stem cell stimulation, or by stem cell differentiation *in vivo*. Clinical studies are performed to prevent development of type 1 diabetes in patients, e.g. by autologous mesenchymal stem cell transplantation, and to develop means for beta-cell imaging by positron emission tomography. We also conduct studies to improve the results of clinical islet transplantation, e.g. by encapsulation in order to avoid immune suppression of the patients.

. In one of these studies, a newly developed oxygenized macrochamber to harbor the islets is tested in a pilot trial with type 1 diabetes patients. The macrodevice protect the islets from immune rejection, whereas oxygen is supplied daily into a refillable oxygen tank.





Fig 2. Micrograph showing vascularization of intraportally transplanted islet with disrupted integrity in the wall of a portal vein tributary. Yellow depicts insulin; red CD31 staining for blood vessels and blue DAPI.

Pancreatic islet blood flow and endocrine function (Leif Jansson)

The overall purpose is to functionally evaluate the vascular system and especially map blood flow regulatory mechanisms in the islets of Langerhans during normal conditions and during various degrees of glucose intolerance and overt diabetes. An important rationale behind these experiments is the diabetes-induced endothelial dysfunction, which also affects the islet vasculature. This detailed knowledge can then be applied to facilitate targeted delivery of substances to the islets by selectively increasing the blood flow to the islets. This is initially performed in experimental animals, but we intend to transfer our results also to humans. Substances of interest for facilitated delivery include immunomodulatory substances, substances stimulating regeneration of beta-cells, contrast agents to increase visibility of islets during imaging procedures for easier quantification of islet mass, substances affecting islet endothelial cells to ameliorate the endothelial dysfunction seen in diabetes, which is generalized but also specifically affects the islets.



In this context we will also study islet endothelial cells (EC) from different animal models and human islets both *in vivo* and *in vitro*.

EC are isolated and cultured under flow with various additions to study the expression of different intracellular and plasma membrane proteins. This will enable us to *e.g.* identify changes in endothelial function caused by hyperglycemia, hyperlipidemia and other conditions associated with

impaired glucose tolerance (IGT). It will also identify endothelial markers, which can be used to further improve selective delivery of substances to the islet vasculature. Changes in endothelial function can then be further evaluated with our palette of *in-vivo* techniques.

On the basis of our findings on normal islet blood flow regulation we will continue our studies to evaluate disturbances occurring during IGT and type 2 diabetes. We have previously observed that these conditions are invariably associated with an increased islet blood flow. Thus, in this context we would be interested to evaluate mechanisms by which to decrease islet blood flow. However, the mechanisms underlying this are as yet largely unknown. We now aim to further clarify these mechanisms and to evaluate to what extent we can normalize islet blood flow. In relation to this, we also plan to investigate if normalization of islet blood flow can ameliorate IGT. We also aim to study, by imaging techniques, if the results on blood flow regulation obtained in rodents are applicable also to humans.

In summary, the general aim is to advance and use our knowledge on islet blood flow regulation to develop techniques to affect islet endocrine function by modulation of islet blood flow. Thereby we will, in a longer perspective, be able to more selectively target drugs to the islets, and facilitate imaging of the islets to obtain improved determinations of beta-cell mass during T1D and T2D.

Members of the group

Per-Ola Carlsson, MD, professor, Senior Consultant in Endocrinology and Diabetology

Leif Jansson, MD, professor

Arne Andersson, MD, professor em.

Joey Lau, associate professor

Monica Sandberg, post-doc

Sara Bohman, post-doc

José Caballero, MD, post-doc

Xiang Gao, post-doc

Carl Johan Drott, MD, PhD student

Hanna Liljebäck, MD/PhD student

Daniel Espes, MD, PhD student

Liza Grapensparr, PhD student

Sara Ullsten, PhD student

Louise Magnusson, PhD student

Astrid Nordin, laboratory engineer

Ing-Britt Hallgren, laboratory engineer

Zhanchun Li, laboratory engineer

My Quach, laboratory engineer

Lisbeth Sagulin, laboratory engineer

Petra Franzen, laboratory engineer

Birgitta Bodin, laboratory technician

Eva Törnelius, laboratory technician

Violeta Armijo Del Valle, research nurse

Rebecca Hilmius, research nurse

Karin Kjellström, research nurse

Publications 2013-

1. Sandberg M., Pettersson U., Henriksnäs J. and L. Jansson L.: The α_2 -adrenoceptor antagonist yohimbine normalizes the increased islet blood flow in GK rats, a model of type 2 diabetes. *Hormone and Metabolic Research* 45:252-254, 2013
2. Chu X., Gao X., Jansson L., Skogseid B. And Barbu A.: Multiple microvascular alterations in pancreatic islets and neuroendocrine tumors of a Men 1 mouse modelneuroendocrine tumors of the Men1 mouse model. *American Journal of Pathology* 182:2355-2367, 2013.
3. Jansson L., Kampf C. and Källskog Ö.: Reinnervation of pancreatic islet grafts in rats: functional stimulation of nerves have minor effects on transplant endocrine function. *Uppsala Journal of medical Sciences* 118:209-216, 2013.
4. Gao X., Sandberg M., Quach M., Bodin B., Johansson L. and Jansson L.: Effects of Mn-DPDP and manganese chloride on hemodynamics and glucose tolerance in anesthetized rats. *Acta Radiologica* 55:328-34, 2014.
5. Gao X., Jansson L., Persson A.E.G. and Sandberg M.: Short-term glucosamine infusion increases islet blood flow in anesthetized rats. *Islets* 5:1-6, 2013.
6. Eriksson O, Espes D, Selvaraju RK, et al. The positron emission tomography ligand [11C]5-hydroxy tryptophan can be used as a surrogate marker from the human endocrine pancreas. *Diabetes* 63:3428-3437, 2014
7. Espes D, Lau J and Carlsson P-O. Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. *Diabetologia* 57:50-53, 2014
8. Espes D, Engström J, Reinius H, Carlsson P-O. Severe diabetic ketoacidosis in combination with starvation and anorexia nervosa at onset of type 1 diabetes : A case report. *Uppsala Journal of Medical Sciences*. 2013;118(2):130-133.
9. Högborg N, Stenbäck A, Carlsson P-O, et al. Genes regulating tight junctions and cell adhesion are altered in early experimental necrotizing enterocolitis. *Journal of Pediatric Surgery*. 2013;48(11):2308-2312.
10. Lai E., Pettersson U., Delgado Verdugo A., et al.: Blood lipids affect rat islet blood flow regulation through b_3 -adrenoceptors. *American Journal of Physiology* 307:E653-E663, 2014
11. Fredriksson F, Christoffersson RH, Carlsson P-O and Lilja HE. Locally increased concentrations of inflammatory cytokines in an intrabdominal adhesion model. *J Pediatr Surg* 49:1480-1484, 2014
12. Sandberg M. and Jansson L.: Effects of cyclo-oxygenase inhibition on insulin release and pancreatic islet blood flow in rats. *Uppsala Journal of Medical Sciences* 119:316-323, 2014.
13. Barbu A., Jansson L., Sandberg M., Quach M. and Palm F.: Measurements of blood flow in single endogenous and transplanted pancreatic islets with hydrogen gas clearance in anesthetized rodents. *Microvascular Research* 97C:124-129, 2014.
14. Zang G., Barbu A., Sandberg M., Carlsson P.-O., Welsh N. and Jansson L.: Activated pancreatic stellate cells and pancreatic islet function in mice. *Uppsala Journal of Medical Sciences*, in press.
15. Gao X, Sandberg M., Lai E., Quach M., Hezel M., Fredholm B.B., Persson A.E.G., Jansson L., and Carlström M.: Abrogation of adenosine A_1 receptor signaling improves metabolism and regulation in aging and obesity. *Diabetologia*, in press.

16. Gao X.: Local purinergic control of arteriolar reactivity in pancreatic islets and renal glomeruli. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1024:1-65, 2014
17. Löfvenborg JE, Andersson T, Carlsson P-O, et al. Coffee consumption and the risk of latent autoimmune diabetes in adults-results from a Swedish case-control study. *Diabet Med* 31:799-805, 2014
18. Rasouli B, Andersson T, Carlsson P-O, et al. Alcohol and the risk for LADA: results based on the Swedish ESTRID study. *Eur J Endocrinol* 171:535-543, 2014
19. Löfvenborg JE, Andersson T, Carlsson P-O, et al. Fatty fish consumption and risk of latent autoimmune diabetes in the adult. *Nutr Diabetes* 2014, Oct 20;4:e139
20. Vågesjö E, Christoffersson G, Essand M, Korsgren O, Carlsson P-O and Phillipson M. Immunological shielding by induced recruitment of regulatory T lymphocytes delays rejection of islets transplanted to muscle. *Cell Transplantation* 24:263-276, 2015
21. Kosykh A, Ngamjarriyawat A, Vasylovska S, et al. Neural crest stem cells from hair follicles and boundary cap have different effects on pancreatic islets in vitro. *Int J NeuroSci* 31:1-21, 2014
22. Espes D, Martinell M and Carlsson P-O. Increased circulating betatrophin concentrations in patients with type 2 diabetes. *Int J Endocrinol* 323407, 2014
23. Ullsten S, Lau J and Carlsson P-O. Vascular heterogeneity between native pancreatic islets determines their fate of survival and revascularization posttransplantation. *Diabetologia* 58:132-139, 2015
24. Espes D, Lau J, Carlsson P-O. Increased levels of irisin in people with long-standing Type1 diabetes. *Diabetic Medicine*. 2015;32(9):1172-1176.
25. Grapensparr L, Vasylovska S, Li Z, et al. Co-transplantation of Human Pancreatic Islets With Post-migratory Neural Crest Stem Cells Increases beta-Cell Proliferation and Vascular And Neural Regrowth. *Journal of Clinical Endocrinology and Metabolism*. 2015;100(4):E583-E590.
26. Hjort R, Alfredsson L, Carlsson P-O, et al. Low birthweight is associated with an increased risk of LADA and type 2 diabetes : results from a Swedish case-control study. *Diabetologia*. 2015;58(11):2525-2532.
27. Lau Börjesson J, Vasylovska S, Kozlova E N, Carlsson P-O. Surface Coating of Pancreatic Islets With Neural Crest Stem Cells Improves Engraftment and Function After Intraportal Transplantation. *Cell Transplantation*. 2015;24(11):2263-2272.
28. Singh K, Kadesjö E, Lindroos J, et al. Interleukin-35 administration counteracts established murine type 1 diabetes - possible involvement of regulatory T cells. *Scientific Reports*. 2015;5:12633.
29. Ullsten S, Grapensparr L, Sandberg M, Carlsson P-O. Schwann cells regulate angiogenesis and blood vessel structure in native and transplanted pancreatic. IPITA/IXA/CTS Joint Congress, NOV 15-19, 2015, Melbourne, AUSTRALIA. *Xenotransplantation*. 2015;22:S46-S46.
30. Zang G, Sandberg M, Carlsson P-O, Welsh N, Jansson L, Barbu A. Activated pancreatic stellate cells can impair pancreatic islet function in mice. *Upsala Journal of Medical Sciences*. 2015;120(3):169-180.

31. Christoffersson G, Waldén T, Sandberg M, Opdenakker G, Carlsson P-O*, Phillipson M*. Matrix metalloproteinase-9 is essential for physiological beta-cell function and islet vascularization in adult mice. *Am J Pathol* 185:1094-1103, 2015. * Shared contribution
32. Carlsson P-O, Schwarcz E, Korsgren O and Leblanc K. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. *Diabetes* 64:587-592, 2015
33. Carlsson P-O and Jansson L. Disruption of insulin receptor signaling in endothelial cells shows the central role of an intact islet blood flow for in vivo β -cell function. *Diabetes* 64:700-702, 2015
34. Carlsson P-O, Korsgren O, Leblanc K. Mesenchymal stem cells to halt the progression of type 1 diabetes? *Curr Diab Rep* 15:46, 2015
35. Espes D, Martinell M, Liljebäck H, Carlsson P-O. Betatrophin in diabetes mellitus: the epidemiological evidence in humans. *Curr Diab Rep* 15:104, 2015
36. Liljebäck H, Grapensparr L, Olerud J, Carlsson P-O. Extensive loss of islet mass beyond the first day after intraportal human islet transplantation in a mouse model. *Cell Transplant* 2015, in press
37. Espes D, Pekna M, Nilsson B, Carlsson P-O. Activation of complement C3 does not hamper the outcome of experimental intramuscular islet transplantation. *Transplantation* 2015, in press
38. Gao X, Sandberg M., Lai E., Quach M., Hezel M., Fredholm B.B., Persson A.E.G., Jansson L., and Carlström M.: Abrogation of adenosine A₁ receptor signaling improves metabolism and regulation in aging and obesity. *Diabetologia* 58:1610-1620, 2015.
39. Li X, Padhan N., Ohlin E., Roche F., Testini C., Stan R.V., Honkura N., Gordon E., Bentley K., Philippides A., Tolmachev V., Dejana E., Vestweber D., Ballmer-Hofer K., Betsholtz C., Pietras K., Jansson L., Claesson-Welsh L.: VEGFR2 pY949 signaling regulates adherens junction integrity and metastatic spread. **Nature Communications**, in press. .
40. Jansson L., Barbu A., Bodin B., Drott C.J., Espes D., Gao X., Grapensparr L., Källskog Ö., Lau J., Liljebäck H., Palm F., Quach M., sand berg M., Strömberg V., Ullsten S. And carlsson P.-O.: Pancreatic islet blood flow and its measurement. *Uppsala Journal of Medical Sciences*, in press.

Agencies that support the work

The Juvenile Diabetes Research Foundation USA

The European Foundation for the Study of Diabetes

The Swedish Research Council

The Swedish Diabetes Association

The Torsten Söderberg Foundation

The Diabetes Wellness Foundation

AFA

The Swedish Juvenile Diabetes Fund

The Novo Nordisk Foundation

The Knut and Alice Wallenberg Foundation
The Olle Engkvist Byggmästare Foundation
The Uppsala-Örebro Regional Research Foundation
The Gunvor & Josef Ane's Foundation
The Thuring Foundation
Svenska Sällskapet för Medicinsk Forsknin
Strategic Funding, EXODIAB
The Family Ernfors Foundation
Goljes Memorial Fund

Islet function in childhood obesity and type 2 diabetes mellitus

Peter Bergsten

Background


The prevalence of persons with metabolic disease including type 2 diabetes mellitus (T2DM) is expected to rise from 3% in 2000 to almost 5% in 2030. Since obesity is strongly linked with T2DM, the increasing prevalence of over-weight and obesity especially among children, reaching 20% in Sweden, is of particular concern. The rise in obesity has a multi-factorial background, where both genetic and environmental factors contribute. Our research focuses on the role and function of the islet of Langerhans in the early stages of obesity and obesity-related complication including T2DM.

Aim

The overall aim is to find therapeutic approaches to halt the rise in childhood obesity and related metabolic disease including T2DM. This will be attempted by applying a translational approach, where obese and lean patients are examined and characterized and underlying mechanisms investigated in islet cellular systems.

Beta-cell function in juvenile type 2 diabetes and obesity (Beta-JUDO)

The FP7 project “Beta-cell function in JUvenile type 2 diabetes Diabetes and Obesity (Beta-JUDO)” started 2012 and will end 2016 and is coordinated from MCB. In the project the role of the beta-cell in development of obesity is addressed. Beta-JUDO encompasses both *in vitro* work, where isolated human islets and beta-cell lines are used, and *in vivo* work, where obese and lean children are examined.



Elevated palmitate concentrations

When isolated islets are exposed to prolonged elevated palmitate levels, as observed in obese subjects and T2DM, insulin secretion is impaired (Fig 1). However, this impaired insulin secretion is preceded by islet insulin hypersecretion (Fig 1; Kristinsson et al 2013). Thus, it appears that before palmitate-induced impairment of insulin secretion and loss of beta-cell mass occur, enhanced insulin secretion is observed.

In young obese and lean children belonging to the “Uppsala Longitudinal Study of Childhood Obesity” (ULSCO) (Forslund et al 2014), we have investigated if the observed palmitate-induced alterations in insulin secretory patterns were evident also *in vivo*. Obese children are referred to the Uppsala University Children’s Hospital, where they are examined and treated. Both the obese children and lean controls are enrolled in the ULSCO cohort, which together with similar patient cohorts in Salzburg, Leipzig and Cambridge form the Beta-JUDO childhood obesity cohort. Circulating palmitate concentrations were determined in the lean and obese subjects (Ubhayasekera et al, 2013). When their insulin secretory response to glucose was measured by oral glucose tolerance test (OGTT), insulin levels at fasting and 30 min of OGTT were accentuated in obese children with elevated palmitate levels but attenuated in obese adolescents with elevated palmitate levels (Fig 2). Indeed, secretory levels in the adolescents were similar to those observed in lean controls. Based on the findings in the isolated islets and the fact that some of these adolescents progressed to overt T2DM, we hypothesized that this “normalization” reflects impaired beta-cell function in the older obese individuals and that insulin hypersecretion observed in isolated human islets (Fig 1) and obese children (Fig 2) is an etiological factor in the development of obesity precipitating overt T2DM in susceptible individuals.

Attenuation of insulin hypersecretion

In isolated islets approaches to attenuate beta-cell hypersecretion are conducted to defining underlying causes for the observed accentuated secretory activity in insulin-producing beta-

Figure 1: Glucose-stimulated insulin secretion from isolated human islets exposed to 0.5 mM palmitate for 0 (open circles), 2 (closed triangles), or 7 (closed squares) days (Stefansson et al, *Diabetes*, 2013).





Figure 2: Oral glucose tolerance test in obese pre-pubertal (top panel) and pubertal (bottom panel) children with high palmitate (closed circles), low palmitate (closed squares) and lean controls (open circles) (Staaf et al, *Ped Res*, 2016).

cells using translational approach. Isolated human islets are exposed to compounds known to affect insulin secretion and their effects on insulin hypersecretion determined. These approaches are expected to give information on pharmacological treatment alternatives for the obese children. In this way antagonist of the G-protein coupled receptor FFAR1, which has palmitate as ligand, was investigated for its effects on insulin hypersecretion (Kristinsson et al, *Endocrinology*, 2013; Kristinsson et al, *BBA*, 2015).

Glucagon/Insulin processing

Accentuated glucagon secretion, was also observed in obese children with high circulating palmitate concentrations (Manell et al, *JCEM*, 2016). We have investigated how elevated levels of glucagon correlate with glucose tolerance in children with obesity. Also, in isolated human islets mechanisms for glucagon hypersecretion are investigated.

Sphingolipids

When palmitate concentrations are elevated the formation of the sphingolipid ceramide is increased. Since this sphingolipid has been implicated in apoptosis we have investigated how sphingolipid metabolism is affected in obesity. This was done by measuring multiple sphingolipid species by GC-MS both in beta-cell exposed to elevated palmitate concentrations (Manukyan et al, 2014) and in the circulation of obese and lean children.

Significance

The results of the project are expected to identify novel principles of normalizing hypersecreting beta-cells. These principles will be evaluated in the young obese individuals as intervention strategies, which are critical since the window of opportunity to preventing impaired beta-cell function and apoptosis in juvenile obesity appears to be limited.

Members of the group

Peter Bergsten, professor

Anders Forslund, docent, senior consultant

Ernest Sargsyan, researcher

Levon Manukyan, postdoctoral person

Anders Alderborn, PhD

Azazul Chowdhury, graduate student

Johan Staaf, graduate student (MD/PhD-programme)

Hjalti Kristinsson, graduate student

Hannes Manell, graduate student (MD/PhD-programme)

Jing Cen, graduate student

Henrik Ström, undergraduate student

Iris Ciba, MD

Marie Dahlbom, research nurse

Malte Lidström, research nurse

Helena Vilén, research dietician
Malin Meirik, research psychologist
Emmelie Brandt, research physiotherapist

Grants

European Commission, FP7, Beta-JUDO
Swedish Medical Research Council
Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning
Swedish Governmental Agency for Innovation Systems
Swedish Diabetes Association
Regional Research Council
Gillberg's Foundation
Family Ernfors' Foundation
Selander's Foundation

Collaborations

Uppsala University:

- Fredrik Ahlsson (Womens's and Children's Health)
- Håkan Ahlström (Radiology)
- Eva Bergman (Womens's and Children's Health)
- Jonas Bergquist (Analytical Chemistry)
- Barbro Diderholm (Womens's and Children's Health)
- Jan Gustafsson (Womens's and Children's Health)

Other universities:

- Ali Moazzami (Swedish University of Agricultural Sciences)
- Antje Körner (University of Leipzig, Germany)
- Reinhard Schneider (EMBL, Germany)
- Daniel Weghuber (Paracelsus Medical University, Salzburg, Austria)
- Kurt Widhalm, (University of Vienna, Austria)
- Jean-Charles Sanchez (University of Geneva, Switzerland)
- Sadaf Farooqi, (University of Cambridge, Great Britain)
- Dave Smith (AstraZeneca, Great Britain)
- Ulrika Hammarström (Scandnavian CRO, Uppsala)

Publications 2013-

1. Mangge H, Zelzer S, Prüller F, Schnedl WJ, Weghuber D, Enko D, **Bergsten P**, Haybäck J and Meinitzer A. Branched chain amino acid are associated with cardiometabolic risk profiles found already in lean, overweight and obese young. *J Nutri Biochem*, 32:123-127, 2016
2. Staaf J, Ubhayasekera SJ, Sargsyan E, Chowdhury A, Kristinsson H, Manell H, Bergquist J, Forslund A and **Bergsten P**. Initial hyperinsulinemia and subsequent beta-cell dysfunction is associated with elevated palmitate levels. *Pediatric Res* doi: 10.1038/pr.2016.80, 2016.
3. Manell H, Staaf J, Manukyan L, Kristinsson H, Cen J, Stenlid R, Ciba I, Forslund A and **Bergsten P**. Altered plasma levels of glucagon, GLP-1 and glicentin during OGTT in adolescents with obesity and type 2 diabetes. *J Clin Endocrinol Metab*. 101:1181-1189, 2016.
4. Kristinsson H, **Bergsten P** and Sargsyan E. Free fatty acid receptor 1 (FFAR1/GPR40) signaling affects insulin secretion by enhancing mitochondrial respiration during palmitate exposure. *BBA* 1853: 3248-3257, 2015.
5. Fred RG, Kappe C, Ameer A, Cen J, **Bergsten P**, Ravassard P, Scharfmann R and Welsh N. Role of the AMP kinase in cytokine-induced human EndoC- β H1 cell death. *Mol Cell Endocrinol* 414: 53-63, 2015.
6. Lundström E, Strand R, Johansson L, **Bergsten P**, Ahlström H and Kullberg J. Magnetic resonance imaging cooling-reheating protocol indicates decreased fat fraction via lipid consumption in suspected brown adipose tissue. *PLoS One* 10: e0126705, 2015.
7. Manukyan L, Ubhayasekera SJ, Bergquist J, Sargsyan E and **Bergsten P**. Palmitate-induced impairments of beta-cell function are linked with generation of specific ceramide species via acylation of sphingosine. *Endocrinology*, 156:802-812, 2015.
8. Forslund A, Staaf J, Kullberg J, Ciba I, Dahlbom M and **Bergsten P**. Uppsala Longitudinal Study of Childhood Obesity – a pediatric cohort addressing childhood obesity. *Pediatrics*, 133:386-393, 2014.
9. Kristinsson H, Smith DM, **Bergsten P** and Sargsyan E. FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion. *Endocrinology*, 154:4078-4088, 2013.
10. Chowdhury A, Satagopam VP, Manukyan L, Artemenko KA, Fung YM, Schneider R, Bergquist J and **Bergsten P**. Signaling in insulin-secreting MIN6 pseudoislets and monolayer cells. *J Proteome Res*, 12:5954-62, 2013.
11. Chowdhury A, Dyachok O, Tengholm A, Sandler S and **Bergsten P**. Functional differences between aggregated and dispersed insulin-producing cells. *Diabetologia* 56:1557-1568, 2013.
12. Ubhayasekera SJ, Staaf J, Forslund A, **Bergsten P**, Bergquist J. Free fatty acid determination in plasma by GC-MS after conversion to Weinreb amides. *Anal Bioanal Chem* 405: 1929-35, 2013.

Physiology of pancreatic islet hormone secretion

Anders Tengholm

The research in our group aims at clarifying the mechanisms regulating the release of insulin, glucagon and other hormones from the islets of Langerhans. Insufficient secretion of blood-glucose-lowering insulin and dysregulated secretion of blood-glucose-elevating glucagon are hallmarks of diabetes. Elucidation of the mechanisms underlying islet hormone secretion and the malfunctions causing diabetes is expected to provide new strategies for treatment of the disease. By combining biochemical and molecular biological techniques with fluorescent cell signalling biosensors and live cell imaging methods, we study the spatio-temporal dynamics of signalling processes regulating secretion in single cells and intact mouse and human pancreatic islets. At present we are focusing on the following issues.

ATP, Ca^{2+} and cAMP signalling in β -cell stimulus-secretion coupling

Insulin is released from β -cells in response to glucose, other nutrients, hormones and neural factors. The hormone is released in pulses with the kinetics determined by a complex interplay between second messengers and signalling proteins beneath the β -cell plasma membrane. Glucose stimulation of β -cells results in uptake and metabolism of the sugar, elevation of the intracellular ATP/ADP ratio, closure of ATP-sensitive K^+ channels in the plasma membrane,

depolarization and voltage-dependent Ca^{2+} influx, which triggers exocytosis of insulin secretory granules. The exocytosis response is amplified by the messenger cAMP, which is generated in β -cells during glucose stimulation as well as upon glucagon and incretin hormone receptor activation. Our lab has discovered that glucose triggers coordinated oscillations of Ca^{2+} and cAMP in β -cells, and that this response is important for pulsatile insulin secretion. During the past year we have also found that impaired glucose-induced cAMP formation contributes to defective insulin secretion from islets cultured under diabetes-like conditions with elevated concentrations of the free fatty acid palmitate (Fig. 1).

Using various cell signalling biosensors we aim to clarify the mechanisms underlying the generation of cAMP oscillations and how the cAMP effectors protein




Figure 1. Recordings of cAMP from individual β -cells within intact mouse pancreatic islets. The green trace shows a representative control recording showing that elevation of the glucose concentration from 3 to 20 mM induces oscillatory cAMP elevation that is reversed when the glucose concentration is restored to 3 mM. Glucagon-like peptide-1 (GLP-1, 100 nM) induces stable cAMP elevation, which is reversed by 5 μM adrenaline. The orange trace shows a similar recording from a β -cell in an islet cultured 48 h in the presence of 0.5 mM palmitate and 1% albumin. Whereas the glucose response is much reduced, the GLP-1-induced cAMP elevation is unaffected. The bar graphs show time-average cAMP elevations \pm s.e.m. in response to 20 mM glucose and GLP-1 in mouse and human β -cells. From Tian et al. Diabetes 64:904-15, 2015.

kinase A and Epac, a guanine nucleotide exchange factor for Rap GTPases, are involved in the regulation of insulin secretion. We have found that protein kinase A, in addition to potentiating exocytosis in response to cAMP-elevating hormones, is important for proper initiation of insulin secretion by glucose. Moreover, recent work from the lab has demonstrated that cAMP and Ca^{2+} signals trigger translocation of Epac to the β -cell plasma membrane. The downstream effects as well as functional importance of these signalling steps are currently under investigation.

Autocrine feedback signalling in β -cells

Exocytosis of insulin granules not only results in the release of insulin, but also of several other granule constituents, which affect β -cell function in an autocrine manner. Activation of insulin receptors leads to PI3-kinase-mediated formation of the phospholipid $\text{PtdIns}(3,4,5)\text{P}_3$. Using fluorescent reporters we have demonstrated that glucose stimulation of β -cells results in pronounced $\text{PtdIns}(3,4,5)\text{P}_3$ oscillations in the plasma membrane that reflect pulsatile insulin secretion and the associated autocrine insulin receptor activation. Although insulin has been found to exert positive feedback on insulin biosynthesis and β -cell proliferation, it is less clear whether insulin acutely stimulates or inhibits insulin secretion.

Insulin is stored in a crystalline complex with Zn^{2+} and this ion is co-released with insulin and exerts feedback effects at multiple levels. The granules also contain ATP and we recently discovered that ATP co-released with insulin activates purinergic P2Y_1 -receptors, which results in phospholipase C activation and short-lived (<10 s), local increases of diacylglycerol (DAG) in the plasma membrane (Fig 2). These DAG spikes results in rapid recruitment and activation of several protein kinase C isoforms. Using various optical single-cell assays we are currently investigating how insulin, Zn^{2+} and ATP affect signalling and secretion in β -cells.




Figure 2. (A) Glucose stimulation of a mouse β -cell triggers pronounced DAG spiking in the plasma membrane that is monitored with a fluorescent DAG reporter. The response is reversibly inhibited when the autocrine action of ATP is blocked with the purinergic receptor antagonist MRS2179.

(B) The DAG spikes are typically spatially confined. Each row shows a sequence of pseudo-colored 14-bit images starting 1 s before the appearance of a DAG spike and displays the DAG reporter fluorescence every second during the following 6 seconds.

Mechanisms controlling the release of glucagon, somatostatin and pancreatic polypeptide

In diabetes there is not only an impaired secretion of insulin, but poor regulation of blood-glucose elevating glucagon contributes to the hyperglycemia underlying diabetes complications. Pancreatic polypeptide is another islet hormone of potential importance for blood glucose regulation by effects on gastric emptying. The fourth islet hormone, somatostatin, is a potent inhibitor of the release of the other hormones and probably has a paracrine function. Other paracrine events in the islets involve insulin-promoted inhibition of glucagon secretion and glucagon-potentiated insulin secretion. Like for insulin, the secretion of glucagon and somatostatin is pulsatile. Our lab has demonstrated that the glucagon pulses are in opposite phase to insulin and somatostatin, which has important implications for the understanding of the action of insulin and glucagon on glucose production in the liver. Glucose inhibits glucagon secretion and stimulates somatostatin secretion but consensus is lacking regarding the underlying mechanisms. Like in β -cells, glucose metabolism plays a key role and Ca^{2+} is the main trigger of exocytosis in both glucagon-releasing α -cells and somatostatin-releasing δ -cells. Fig. 3 illustrates our present working model for glucose regulation of glucagon secretion.




Figure 3. Model for glucose regulation of glucagon release. (A) In the 1-7 mM range (G1, G7), glucose controls glucagon release via an intrinsic non- K_{ATP} channel-dependent mechanism in α -cells and paracrine release of somatostatin from δ -cells has only a tonic inhibitory effect. (B) The graph showing glucose inhibition of glucagon secretion is expressed in percent of stimulated secretion at 1 mM glucose. To get an impression of the relative magnitudes of the corresponding insulin and somatostatin responses, their secretion are expressed in percent of stimulated secretion in response to 0.5 mM tolbutamide. (A, C) At 20 mM glucose (G20) the K_{ATP} -independent mechanism no longer stimulates glucagon secretion and the pulsatility is generated via paracrine release of inhibitory factors from β - and δ -cells. The question mark indicates that a stimulatory effect of high glucose in the α -cell is not necessarily K_{ATP} channel-dependent. Hormone secretion data have been recalculated as percentage of estimated secretion at 1 mM glucose (From Gylfe Diabetes 62:1391-1393, 2013).

We are currently investigating intracellular ATP, Ca^{2+} and cAMP signalling in relation to hormone release from the different islet cells as well as the importance of paracrine intercellular communication for generating the different secretory patterns. Fig. 4 shows Ca^{2+} recordings from α - and β -cells within the same islet. This experiment illustrates that α -cells show Ca^{2+} oscillations at 3 mM glucose, which is too low to activate the β -cells. Elevation of the glucose concentration to 20 mM causes a temporary interruption of Ca^{2+} signaling in the α -cells and induces well-synchronized Ca^{2+} oscillations in β -cells. α -cell Ca^{2+} signaling is subsequently restored with Ca^{2+} oscillations that are synchronized not only among different α -cells but also between α - and β -cells. These findings are unexpected in light of the suppressed glucagon secretion and the anti-phase pulses of glucagon and insulin (Fig. 3), and indicate that glucagon release may be controlled by somatostatin in a Ca^{2+} -independent manner.




Figure 4. The graphs show average cytoplasmic Ca^{2+} concentrations (red for α - and green from β -cells \pm s.e.m. (pink for α - and light green for β -cells) for all 13 α -cells and 6 β -cells in a single mouse islet loaded with the fluorescent Ca^{2+} indicator fluo-4 and with red fluorescent protein expression in the α -cells. The vertical yellow background areas are aligned to glucose-induced peaks of the Ca^{2+} oscillations in the β -cells. The coloured area in the bottom panel shows a two-dimensional cross-correlogram with time on the x axis and the lag time of the correlation on the y axis and the normalized cross-correlation amplitude coded in color. From Li et al, FASEB J 29:3379-88, 2015.

Members of the group

Parvin Ahooghalandari – Research engineer
 Ida Alenkvist – Graduate student
 Helene Dansk -Research engineer
 Oleg Dyachok – Senior research engineer
 Eva Grapengiesser - Associate professor
 Erik Gylfe - Professor
 Bo Hellman - Professor
 Lisen Kullman - Researcher
 Jia Li – Postdoc
 Vishal Parekh – Postdoc
 Hongyan Shuai – Graduate student
 Anders Tengholm – Professor
 Antje Thonig – Laboratory technician
 Yunjian Xu - Senior research engineer
 Qian Yu – Graduate student

Agencies that support the work

The Diabetes Wellness Foundation
 The European Foundation for the Study of Diabetes
 The Swedish Research Council
 The Swedish Diabetes Association
 Novo Nordisk Foundation
 Family Ernfors Foundation

Publications 2013-

1. Tuomi T, Nagorny C, Singh P, Bennet H, Yu Q, Alenkvist I, Isomaa B, Östman B, Söderström J, Pesonen AK, Martikainen S, Räikkönen K, Forsén T, Hakaste L, Almgren P, Storm P, Asplund O, Scherbina L, Fex M, Fadista J, Tengholm A, Wierup N, Groop L, Mulder H. 2016. Increased melatonin signaling is a risk factor for type 2 diabetes. *Cell Metab* 23, in press.
2. Li J, Yu Q, Ahooghanaldari P, Gribble FM, Reimann F, Tengholm A, Gylfe E. 2015. Submembrane ATP and Ca^{2+} kinetics in α -cells: unexpected signalling for glucagon secretion. *FASEB J* 29:3379-88
3. Wan Saudi WS, Halim MA, Rudholm-Feldreich T, Gillberg L, Rosenqvist E, Tengholm A, Sundbom M, Karlom U, Näslund E, Webb DL, Sjöblom M, Hellström PM. 2015. Neuropeptide S inhibits gastrointestinal motility and increases mucosal permeability through nitric oxide. *Am J Physiol Gastrointest Liver Physiol*, 309:G625-G634.
4. Tian G, Sol EM, Xu Y, Shuai H, Tengholm A. 2015. Impaired cAMP generation contributes to defective glucose-stimulated insulin secretion after long-term exposure to palmitate. *Diabetes* 64:904-15.
5. Tengholm A, Idevall-Hagren O. 2015. Imaging sub-plasma membrane cAMP dynamics with fluorescent translocation reporters. *Methods Mol Biol* 1294:85-101.
6. Tengholm A. 2014. P2Y₁ receptors take centre stage in autocrine stimulation of human beta cells. *Diabetologia* 57:2436-2439.
7. Alenkvist I, Dyachok O, Tian G, Li J, Mehrabanfar S, Jin Y, Birnir B, Tengholm A, Welsh M. *J Endocrinol* 223:267-75.
8. Hellman B, Dansk H, Grapengiesser E. 2014. Activation of α adrenergic and muscarinic receptors modifies early glucose suppression of cytoplasmic Ca^{2+} in pancreatic β -cells. *Biochem Biophys Res Commun* 445:629-32.
9. Hellman B, Grapengiesser E. 2014. Glucose-induced inhibition of insulin secretion. *Acta Physiol* 210:479-88.
10. Gylfe E. 2013. Glucose control of glucagon secretion: there is more to it than K_{ATP} channels. *Diabetes* 62:1391-3.
11. Gylfe E. 2013. Comment on: Allister et al. UCP2 regulates the glucagon response to fasting and starvation. *Diabetes* 62:e11. Doi 10.2337/db13-0397.
12. Li J, Shuai HY, Gylfe E, Tengholm A. 2013 Oscillations of sub-membrane ATP in glucose-stimulated beta-cells depend on negative feedback from Ca^{2+} . *Diabetologia* 56:1577-86.
13. Idevall-Hagren O, Jakobsson I, Xu YJ, Tengholm A. 2013. Spatial control of Epac2 activity by cAMP and Ca^{2+} -mediated activation of Ras. *Science Signal* 6:ra29. doi: 10.1126/scisignal.2003932.
14. Høivik EA, Witsø SL, Bergheim IR, Xu YJ, Jakobsson I, Tengholm A, Døskeland SO, Bakke M. 2013. DNA methylation of alternative promoters directs tissue specific expression of Epac2 isoforms. *PloS ONE* 8:e67925.
15. Chowdhury, Dyachok O, Tengholm A, Sandler S, Bergsten P. 2013. Functional differences between aggregated and dispersed insulin-producing cells. *Diabetologia* 56:1557-68.

16. Mokhtari D, Al-Amin A, Turpaev K, Li T, Idevall-Hagren O, Li J, Wuttke A, Fred RG, Ravassard P, Scharfmann R, Tengholm A, Welsh N. 2013 Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl. *Diabetologia* 56:1327-38.
17. Wuttke A, Idevall-Hagren O, Tengholm A. 2013 P2Y₁ receptor-dependent diacylglycerol signaling microdomains in β cells promote insulin secretion. *FASEB J* 27:1610-1620.
18. Zeller KS, Riaz A, Sarve H, Li J, Tengholm A, Johansson S. 2013. The role of mechanical force and ROS in integrin-dependent signals. *PloS ONE*, 8:e64897.
19. Zang G, Christoffersson G, Tian G, Harun-Or-Rashid M, Vågesjö E, Phillipson M, Barg S, Tengholm A, Welsh M. 2013 Aberrant association between vascular endothelial growth factor receptor-2 and VE-cadherin in response to vascular endothelial growth factor-a in Shb-deficient lung endothelial cells. *Cell Signal* 25:85-92.

Reviews 2013-

20. Gylfe E. 2016. Glucose control of glucagon secretion – ‘There’s a brand-new gimmick every year’. *Ups J Med Sci* 4:1-13.
21. Gylfe E, Tengholm A. 2014. Neurotransmitter control of islet hormone pulsatility. *Diabetes Obes Metab* 16:102-110.
22. Gylfe E, Gilon P. 2014. Glucose regulation of glucagon secretion. *Diabetes Res Clin Pract* 103:1-10.

Cellular architecture and organelle communication

Olof Idevall-Hagren

The architecture of the prototypic mammalian cell has been the focus of intense study since the early days of microscopy. With the development of electron microscopy for the biological sciences in the 1950's came the detailed characterization of most cellular organelles, like the endoplasmic reticulum (ER), mitochondria, the Golgi apparatus and secretory vesicles. More recently, using live cell imaging techniques, it has been found that these organelles are highly dynamic structures that constantly reform, reshape and redistribute within the cell. Many organelles also seem to communicate through direct contacts, formed by protein and lipid complexes. At these sites, information flow between the organelles in the form of lipids, ions and proteins help control the specific organelle function. Using high-resolution fluorescence microscopy together with genetically encoded biosensors and molecular tools we study and manipulate these cellular structures in order to better understand their function.

Organelle dynamics in β -cells

Malfunctioning β -cells strongly contributes to diabetes development and progression by failing to secrete sufficient amounts of insulin. Insulin is produced in the ER and stored in granules




Figure 1: *A. Electron micrograph of a fibroblast where the ER is stained black. Notice how parts of the ER are in close proximity of the cell periphery (red box). B. Schematic illustration depicting Extended-Synaptotagmin-1 (E-Syt1), an ER-anchored protein that also binds the plasma membrane by interactions with specific lipids. C. Confocal microscopy images of a very flat cell expressing fluorescence-tagged E-Syt1 under conditions where the cytoplasmic Ca^{2+} concentration is low or high. Notice how the molecules aggregate at the plasma membrane when the Ca^{2+} concentration increases.*

in a Ca^{2+} -dependent manner that coincide in space and time with secretion, indicating a direct involvement of the ER in the regulation of insulin secretion (Figure 2). Current work aims at: 1) characterizing the role of E-Syts in β -cell function, 2) identifying other proteins that accumulate at these membrane contact sites, 3) investigating whether these structures are altered in diabetic β -cells. Hopefully this can help us better understand how altered ER function contributes to the progression of diabetes.





Figure 2: *Figure shows glucose induced oscillations of the cytosolic Ca^{2+} concentration (red) and the corresponding recruitment of the ER-localized E-Syts (black) to the plasma membrane. The gray area is shown below on an expanded time axis. Notice the close association between changes in Ca^{2+} and binding of E-Syts to the plasma membrane.*

Optogenetic tool development and implementation

Optogenetics is the modification and use of light-regulated proteins, typically isolated from plants or bacteria, to enable control of cellular processes by illumination. Expression of optogenetic tools has for example enabled light-dependent control of neurotransmitter release, insulin release, cell migration and transcription. We have previously developed tools that allows light-dependent recruitment of lipid synthesizing and degrading enzymes to the plasma membrane, leading to the discovery that rapid changes in lipid levels can polarize cells and is sufficient to induce e.g. directed cell migration. We have also used these tools to demonstrate



that the ER is physically tethered to the plasma membrane through the interaction of the ER-localized E-Syts with the anionic plasma membrane lipid PI(4,5)P₂. This lipid regulates a plethora of other functions of importance for β -cell function, including ion fluxes and exocytosis, but to what extent the lipid actually control any of these processes under physiological settings is unknown. We are currently using adenoviral versions of

Figure 2: A,B. Drawing showing the principle of light-induced hetero-dimerization. One part of the optogenetic module (CIBN) can be anchored to any cellular membrane (target membrane) whereas the other part (CRY2) can be fused to a protein of interest (here a Red Fluorescent Protein). Blue-light illumination promotes the interaction between CIBN and CRY2 and causes redistribution of the protein of interest to the target membrane. **C.** Focal blue-light illumination (blue square) allows recruitment of a lipid-degrading enzyme (green) to a restricted part of the plasma membrane, resulting in corresponding loss of a specific lipid (red).

these optogenetic tools together with measurements of Ca²⁺ concentration changes and insulin secretion to manipulate PI(4,5)P₂ levels in intact mouse and human β -cells. We will also further develop these optogenetic tools to allow formation of inducible contacts between various cellular organelles and to alter organelle distribution within cells in order to determine how organelle tethers and distribution affects β -cell function. Since optogenetics is a non-invasive technique, we also work on adapting it to *in vivo* settings. Additionally, we are developing, together with a group at Zhejiang University, a light-array that will enable high-throughput optogenetic manipulations.

Publications 2013-

1. Idevall-Hagren, O., Lu, A., Xie, B., De Camilli, P., Triggered Ca²⁺ influx is required for extended synaptotagmin 1-induced ER-plasma membrane tethering. Idevall-Hagren O, Lü A, Xie B, De Camilli P. EMBO J. 2015 Sep 2;34(17):2291-305.
2. Tengholm A, Idevall-Hagren O. Imaging Sub-plasma Membrane cAMP Dynamics with Fluorescent Translocation Reporters. Methods Mol Biol. 2015;1294:85-101.

3. Pirruccello M, Nandez R, Idevall-Hagren O, Alcazar-Roman A, Abriola L, Berwick SA, Lucast L, Morel D, De Camilli P. Identification of Inhibitors of Inositol 5-Phosphatases through Multiple Screening Strategies. *ACS Chem Biol*. 2014 May 1. PMID: 24742366.
4. Idevall-Hagren O, De Camilli P. Manipulation of plasma membrane phosphoinositides using photoinduced protein-protein interactions. *Methods Mol Biol*. 2014;1148:109-28. PubMed PMID: 24718798.
5. Giordano F, Saheki Y, Idevall-Hagren O, Colombo SF, Pirruccello M, Milosevic I, Gracheva EO, Bagriantsev SN, Borgese N, De Camilli P. PI(4,5)P(2)-dependent and Ca(2+)-regulated ER-PM interactions mediated by the extended synaptotagmins. *Cell*. 2013 Jun 0;153(7):1494-509. PMID: 23791178
6. Idevall-Hagren O, Jakobsson I, Xu Y, Tengholm A. Spatial control of Epac2 activity by cAMP and Ca²⁺-mediated activation of Ras in pancreatic β cells. *Sci Signal*. 2013 Apr 30;6(273):ra29.1-11, S1-6. PMID: 23633676.
7. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl. Mokhtari D, Al-Amin A, Turpaev K, Li T, Idevall-Hagren O, Li J, Wuttke A, Fred RG, Ravassard P, Scharfmann R, Tengholm A, Welsh N. *Diabetologia*. 2013 Jun;56(6):1327-38. doi: 10.1007/s00125-013-2868-2.
8. Wuttke A, Idevall-Hagren O, Tengholm A. P2Y receptor-dependent diacylglycerol signaling microdomains in β cells promote insulin secretion. *FASEB J*. 2013 Apr;27(4):1610-20. PMID: 23299857.

Reviews 2013-

1. Idevall-Hagren O, De Camilli P. Detection and manipulation of phosphoinositides. *Biochim Biophys Acta*. 2015 Jun;1851(6):736-745.

Members of the group

Olof Idevall-Hagren – Assistant Professor

Antje Thonig – Laboratory technician

Beichen Xie – PhD student

Phuoc My Nguyen - PhD student

Agencies that support the work

The Swedish Research Council

The Göran Gustafsson foundation

The Malin and Lennart Philipson foundation

Novo Nordisk foundation

STINT

Magnus Bergwalls stiftelse

Mechanisms of regulated exocytosis

Sebastian Barg

Exocytosis is fundamental to every cell and crucial to intracellular transport, protein sorting, and cell-to-cell communication. In both neurons and endocrine cells, exocytosis leads to the release of neurotransmitters and hormones, and defects in this process can underlie disease, such as type-2 diabetes. In our lab we are interested in the cell biology of insulin secretion, with a focus on the life-cycle of insulin-containing secretory granules. We study exocytosis in pancreatic β -cells using advanced light microscopy (TIRF, super-resolution and single molecule imaging) in combination with electrophysiology. Both methods are sensitive enough to observe single granules and even individual protein molecules in a living cell

Molecular architecture of the insulin granule release site


Every β -cell contains thousands of secretory granules that store insulin. When blood glucose is elevated, these granules undergo regulated exocytosis and release the hormone into the blood stream. Before this can happen, granules have to reach the plasma membrane, where they “dock” and then assemble the exocytosis machinery. When insulin is released, these steps quickly become limiting for how much insulin is released.

The docking process is not understood in molecular terms, but many of the proteins involved have been identified. One hypothesis that we are currently testing is that some of these proteins (including t-SNAREs) pre-assemble at small hotspots in the plasma membrane. These hotspots, perhaps related to lipid rafts, may then recruit granules and act as “launching pads” for exocytosis. There is evidence that this docking step is impaired in type-2 diabetes, and the most important “diabetes gene” affects expression of a protein involved in granule docking. How do cells compartmentalize their plasma membrane to organize such sites? Which proteins are recruited to these hotspots, when, and at how many copies? And how are docking sites regulated and what distinguishes release-ready granules from those that are merely docked?


The three SNARE proteins syntaxin, SNAP25 and synaptobrevin are central to membrane fusion during exocytosis. Since two of these, the t-SNAREs syntaxin and SNAP-25 inhabit the plasma membrane, one expects them to collect at the exocytic site before a vesicle or granule can fuse there. Indeed, we found t-SNAREs cluster near docked granules and quantitative image analysis shows association of GFP-labeled syntaxin and SNAP25 with granules in live Ins1- or PC12-cells. The interaction depends on the N-terminal Habc domain of syntaxin, rather than formation of a SNARE complex. Up to 70 molecules of syntaxin are recruited to the granule site during docking, and lost during undocking and exocytosis. However, individual molecules of both proteins diffuse rapidly in the plasma membrane and are only occasionally captured beneath a granule, for a short time (<1 s). Thus, the protein composition of individual granule-associated nanodomains is remarkably dynamic and correlates with the granules' ability to exocytose. This organization is established during or just after granule docking, which suggests that granules approaching the plasma membrane might induce the formation of their own docking site. Dynamic association of exocytosis proteins with individual granules occurs on a timescale consistent with rapid cellular signaling, and may be important for the short-term regulation of insulin secretion (Barg et al PNAS 2010; Knowles et al PNAS 2010). We have until now quantified to over 20 other exocytosis proteins (syntaxin, SNAP25, munc18, munc13, rab3 etc) , and established the time course of their recruitment to the the insulin

granule release site. These measurements show that insulin granule docking coincides with rapid *de novo* formation of syntaxin1/munc18 clusters at the nascent docking site, which stabilizes the docked state. Interfering with this clustering prevents docking. We could also show that the proteins SNAP25 and munc13 are recruited to the docking site with a delay of at least a minute, consistent a role in granule priming rather than docking. We conclude that secretory vesicles dock by inducing syntaxin1/munc18 clustering in the target membrane, and find no evidence for preformed docking receptors.

Our work is unique in that we have correlated release probability of individual docking/undocking events with local protein recruitment. We provide the first quantitative timecourse for the assembly of the release site, which puts constraints on molecular models of docking and exocytosis. For example, we show that Ca^{2+} -channels, SNAP25 and munc13 are not detectable at the release site for at least 30 s after docking, implying that these proteins are recruited as part of secretory vesicle priming, rather than docking. This is not due to limits in sensitivity, as our method can detect specific association of on average less than one labeled molecule with the docking site. To our knowledge, this is also the first time that the formation of protein-containing membrane rafts has been directly visualized and quantified in living cells.



A single molecule of Syx-EGFP (green) binds to a secretory granule (NPY-cherry, red). Scalebar 1 μm ; 20ms per frame.



Quantification of protein affinity during the lifecycle of the docking/release site. (Gandasi and Barg, *Nat Comm* i2014).

Publications 2013-

1. Barg S and Gucek A (2016). How kiss-and-run makes us sick: Sox4 puts a break on the pore *Diabetes*, in press
2. Gandasi NR, Vestö K, Helou M, Yin P, Saras J, **Barg S.** (2015) Survey of Red Fluorescence Proteins as Markers for Secretory Granule Exocytosis. *PLoS One* 10:e0127801.
3. NR Gandasi and S Barg (2014). Contact-induced clustering of syntaxin and munc18 docks secretory granules at the exocytosis site. *Nature Communications* 5:3914
4. Krus U, King B, Nagaraj, Gandasi NR, Zhang E, Barg S, Blom AM, and Renström E (2013). The complement inhibitor CD59 plays a fundamental role in insulin secretion by controlling recycling of exocytotic fusion proteins. *Cell Metabolism* 19:883-90
5. G Zang, G Christoffersson, G Tian, M Harun-Or-Rashid, E Vågesjö, M Phillipson, S Barg, A Tengholm, and M Welsh (2013). Aberrant association between Vascular Endothelial Growth Factor Receptor-2 and VE-cadherin in response to Vascular Endothelial Growth Factor-A in Shb-deficient lung endothelial cells. *Cellular Signalling* 25:85-92
6. Y Jin, S Korol, Z Jin, S Barg and B Birnir (2013). In intact rat islets interstitial GABA activates GABAA channels that generate tonic currents in the α -cells. *PloS ONE* 8:e67228
7. Iglesias J, Barg S, Vallois D, Lahiri S, Roger C, Yessoufou A, Pradevand S, McDonald A, Bonal C, Reimann F, Gribble F, Debril MB, Metzger D, Chambon P, Herrera P, Rutter GA, Prentki M, Thorens B, Wahli W. PPAR β/δ affects pancreatic β cell mass and insulin secretion in mice. *J Clin Invest.* 2012, 122:4105-17.
8. Zang G, Christoffersson G, Tian G, Harun-Or-Rashid M, Vågesjö E, Phillipson M, Barg S, Tengholm A, Welsh M. Aberrant association between vascular endothelial growth factor receptor-2 and VE-cadherin in response to vascular endothelial growth factor-a in Shb-deficient lung endothelial cells. *Cell Signal.* 2013, 25:85-92

Members of the group

Sebastian Barg - Docent

Nikhil Gandasi- postdoc

Yin Peng, Graduate student

Omar Hmeadi, Graduate student

Emma Kay, postdoc

Jan Saras, research engineer

Maria Helou, project student SOFOSKO

Per-Eric Lund, research engineer

Misty Marshall, postdoc

Alenka Gucek, postdoc

Agencies that support the work

Diabetes Research Wellness Foundation

Swedish Research Council (Vetenskapsrådet)

Barndiabetesfonden

Novo Nordisk Foundation

European Foundation for the Study of Diabetes/MSD

European Foundation for the Study of Diabetes/BI

The Carl Tryggers Foundation

The Göran Gustafsson Foundation

Family Ernfors Foundation


OE och Edla Johanssons stiftelse

PO Zetterlings stiftelse

The functional organisation of the T cell plasma membrane

Ingela Parmryd

The plasma membrane of eukaryotic cells contains nanodomains, commonly referred to as lipid rafts, which are more ordered than the rest of the plasma membrane. The high order is generally considered homologous to the tight packing of cholesterol and sphingolipids observed in model membranes. However, we have recently demonstrated that lipid rafts form when actin filaments are pinned to the plasma membrane via phosphoinositides and when extracellularly exposed receptors are pinned by antibodies (Dinic et al., 2013), suggesting that the mechanism for lipid raft formation is lipid-protein interactions. We have shown that T cell signalling is initiated upon lipid raft aggregation that can be triggered by cold stress and changes in the plasma membrane lipid composition. We have recently shown that the T cell receptor in resting T cells resides in lipid rafts that are brought together upon receptor engagement (Dinic et al., 2015). We are now investigating what is triggering the formation of lipid rafts in more detail and how membrane order affects the molecular clustering that accompanies T cell signalling using techniques like superresolution microscopy and fluorescence correlation spectroscopy.



localisation of the T cell receptor. The TCR is found in ordered plasma membrane domains that form where actin filaments are pinned to the plasma membrane. To scan the environment TCR-containing ordered domains at the tip of membrane protrusions positions the receptor at an ideal position. From Dinic et al., 2015.

The cell surface is neither flat nor smooth but surface topography is ignored in current models of the plasma membrane. Using high resolution topographical maps of live cells, we and our collaborators have demonstrated that apparent topographical trapping is easily mistaken for elaborate membrane model features like hop diffusion and transient anchorage. Even binding could be the result of apparent topographical trapping when single particle tracks are interpreted in 2D although the molecules are moving in 3D. We are now together with collaborators at CBA at UU developing a method to analyse diffusion coefficients on non-flat surfaces.

$\gamma\delta 2$ is a T cell subset that is activated by phosphoantigens, small organic compounds with phosphate groups. Together with collaborators we have found that media from erythrocytes infected with *P. falciparum* can stimulate $\gamma\delta 2$ T cell proliferation (Lindberg et al., 2013) suggesting that phosphoantigens both are produced in and secreted from these cells. We now address at which parasite stage this production occurs and what metabolic pathway is responsible for the production and how phosphoantigens affect the plasma membrane organisation of signalling molecules.

We also develop image analysis software to get quantitative and objective answers to our questions. We have developed and patented the method RBNCC (replicate based noise corrected correlation) where image noise, which is unavoidable and leads to the underestimation of the underlying correlation, can be eliminated from correlation measurements. We have performed detailed studies on coefficients developed for use in colocalisation analyses revealing that several are not fit for their purpose. We advocate that colocalisation analysis should be divided into the two subgroups co-occurrence and correlation (Adler & Parmryd, 2013) and that only pixels where both fluorophores are present should be included in correlation analyses (Adler & Parmryd, 2014). We now investigate how deconvolution affects correlation analysis and how different intracellular distributions of

molecules are represented by our division of colocalisation analysis into co-occurrence and correlation.

Members of the group

Ingela Parmryd, associate professor

Jeremy Adler, research engineer

Warunika Aluthgedara, project assistant

Love Chrisson, undergraduate student

Parham Ashrafzadeh, graduate student

Chenxiao Liu, graduate student

Jan Saras, research engineer

Publications 2013-

1. Adler, J, Parmryd, I. (2013) Colocalization analysis in fluorescence microscopy. *Methods Mol. Biol.* 931, 97-109
2. Dinic J, Ashrafzadeh P, Parmryd I. (2013) Actin filaments at the plasma membrane in live cells cause the formation of ordered lipid domains. *Biochim. Biophys. Acta.* 1828, 1102-1111
3. Parmryd I, Önfelt B. (2013) Consequences of membrane topography. *FEBS J.* 280, 2775-2784
4. Lindberg B, Merritt EA, Rayl M, Liu C, Parmryd I, Olofsson B, Faye I. (2013) Immunogenic and antioxidant effects of a pathogen-associated prenyl pyrophosphate in *Anopheles gambiae*. *PLoS One* 8, e73868
5. Adler J, Parmryd I. (2014) Quantifying Colocalisation: empty pixels, thresholding and the Hcoef. *PLoS One* 9:111983
6. Mahammad S, Parmryd I. (2015) Cholesterol depletion using methyl- β -cyclodextrin. *Methods Mol. Biol.* 1232, 91-102
7. Ashrafzadeh P, Parmryd I. (2015) What can different methods tell us about membrane nanodomains in cells? *Essays Biochem.* 57, 57-68.
8. Riehl A, Dinic J, Adler J, Parmryd I. (2015) The T cell receptor resides in small ordered plasma membrane domains that aggregate upon patching of the receptor. *Sci. Rep.* 5:10082

Licentiate theses

Parham Ashrafzadeh: The role of actin filaments and phosphatidylinositol (4,5) biphosphate in the formation of ordered plasma membrane domains. April 2015.

Chenxiao Liu: V γ 9V δ 2 T cell activation by phosphoantigens released by *Plasmodium falciparum* infected erythrocytes. December 2015.


Agencies that support the work

The Swedish Research Council

Importance of Shb-dependent signaling for angiogenesis and hematopoiesis

Michael Welsh

Shb is an SH2-domain adapter protein operating downstream of tyrosine kinase receptors such as VEGFR-2, FGFR-1, PDGF-receptors and the T cell receptor. The effects of Shb are pleiotropic and context dependent. We have recently generated a *Shb*-knockout mouse to assess the physiological relevance of Shb in vivo.



We observe impaired glucose homeostasis due to insufficient insulin secretion in *Shb*-deficient mice. In addition, the β -cells exhibit reduced stress sensitivity. These effects appear to be a consequence of constitutive FAK activation.

Shb-knockout mice display reproductive abnormalities with a transmission ratio distortion of the knockout allele related to female reproduction. Consequently, oocyte maturation is impaired in the absence of Shb and this relates to abnormal signaling via the ERK-RSK-S6 pathway. In addition to aberrant oocyte maturation, *Shb*-knockout embryos are morphologically abnormal and do not implant well.

Shb-knockout mice also display reduced angiogenesis and this causes diminished tumor expansion (subcutaneously injected tumor cells or inheritable RIP-Tag insulinomas). *Shb* deficient endothelial cells have abnormal cytoskeleton and adherens junctions that may contribute to deficient angiogenesis. In addition, *Shb*-knockout vascular physiology shows signs of compensatory mechanisms (increased blood flow velocity and an increased frequency of intermediately sized arterioles as determined by micro-CT) to counteract the adverse effects

of the endothelial dysfunction. Although vascular performance under normal conditions appears relatively unaffected by the absence of *Shb*, recovery after ischemia was found to be impaired in both the cremaster and hindlimb muscles, which was primarily dependent on *Shb* deficiency in the vasculature and not in myeloid cells. Multiple signalling abnormalities in *Shb* knockout endothelial cells were noted, included elevated basal and reduced VEGF-stimulated FAK, ERK, Akt and Rac1 activities. The absence of *Shb* increases melanoma metastasis and the studies aim at identifying mechanisms explaining this finding.

The absence of *Shb* exerts effects on hematopoiesis and peripheral T lymphocyte function. CD4⁺ T lymphocytes show a Th2 skewing of their response to stimulation in the absence of *Shb* and this could be of relevance for understanding allergic responses. *Shb* knockout hematopoietic stem cells show lower rates of proliferation due to elevated FAK signalling. Development of BCR-ABL1-induced leukemia was accelerated in the absence of *Shb*, again due to elevated FAK activity. Further studies will be conducted in order obtain a better understanding of *Shb* in leukemia.

Our current research effort is mainly focussed on investigating:

- A) The relevance of vascular dysfunction as a consequence of *Shb* deficiency for tumor metastasis
- B) The development of leukemia in relation to *Shb* deficiency

Members of the group

Michael Welsh - Professor

Björn Åkerblom- Post-Doc

Maria Jamalpour – PhD-student

Xiujuan Li- Post-doc

Publications 2013-2015

1. Zang, G., Christoffersson, G., Tian, G., Harun-Or-Rashid, M., Vågesjö, E., Phillipson, E., Barg, S., Tengholm, A., Welsh, M. Isolated lung endothelial cells from *Shb* knockout mice show aberrant association between Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) and VE-cadherin in response to VEGF-A. *Cell. Signal.*, 25, 85-92, 2013
2. Gustafsson, K., Heffner, G., Wenzel, PL., Curran, M., Grawé, J., McKinney-Freeman, SL., Daley, GQ., Welsh, M. The Src homology 2 protein *Shb* promotes cell cycle progression in murine hematopoietic stem cells by regulation of focal adhesion kinase activity. *Exp Cell Res*, 319, 1852-1864, 2013
3. Gustafsson, K., Willebrand, E., Welsh, M. Absence of the adapter protein *Shb* potentiates the T helper type 2 response in a mouse model of atopic dermatitis. *Immunology*, 143, 33-41, 2014
4. Gustafsson, K., Jamalpour, M., Trinh, C., Kharas, MG, Welsh, M. The Src homology-2 protein *Shb* modulates FAK signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease. *J Hematol Oncol*, 7:45, 2014
5. Alenkvist, I., Dyachok, O., Tian, G., Li, J., Mehrabanfar, S., Jin, Y., Birnir, B., Tengholm, A., Welsh, M. Absence of *Shb* impairs insulin secretion by elevated FAK activity in pancreatic islets. *J Endocrinol*, 223, 267- 275, 2014

6. Nikpour, M, Gustafsson, K., Vågesjö, E., Seignez, C., Giraud, A., Phillipson, M., Welsh, M. *Shb* deficiency in endothelium but not in leukocytes is responsible for impaired vascular performance during hindlimb ischemia. *Acta Physiologica*, 214, 200-209, 2015 doi: 10.1111/apha.12448, 2015
7. Zang, G., Gustafsson, K., Jamalpour, M., Hong, J., Genové, G., Welsh, M. Vascular dysfunction and increased metastasis of B16F10 melanomas in *Shb* deficient mice as compared with their wild type counterparts. *BMC Cancer*, 15, 234, 2015, DOI: 10.1186/s12885-015-1269-y, 2015
8. Massena, S., Christoffersson, G., Vågesjö, E., Seignez, C., Gustafsson, K., Binet, F., Hidalgo, C. H., Giraud, A., Lomei, J., Weström, S., Shibuya, M., Claesson-Welsh, L., Gerwins, P., Welsh, M., Kreuger, J. and Phillipson, M. Identification and characterization of VEGF-A-responsive neutrophils expressing VEGFR1, CD49d and CXCR4 in mice and humans. *Blood*, 126, 2016-2026, 2015, doi: 10.1182/blood-2015-03-631572, 2015

Reviews 2013-2015

Claesson-Welsh, L. and Welsh, M. VEGFA and tumor angiogenesis. *J. Int. Med.*, 273, 114-127, 2013

Book chapters 2013-2015

Philipsson, M, Christoffersson G., Claesson-Welsh, L. Welsh, M. VEGFA-induced vascular permeability and leukocyte extravasation. Chapter 8 (pages 187-208) in: *Endothelial signaling in development and disease*. Springer New York Heidelberg Dordrecht London, 2015. Editors: Liebner, S. and Schmidt, M. DOI 10.1007/978-1-4939-2907-8.

Agencies that support the work

The Swedish Cancer Foundation

Stiftelsen Familjen Ernfors fond

EXODIAB

Complications in pregnancy

Ulf Eriksson, Parri Wentzel

We are studying different types of pregnancy complications, resulting in disturbed embryo-fetal development as a consequence of altered maternal metabolism (caused by diabetes, obesity, or ethanol intake). Our short-term aims are to clarify and understand the mechanisms and patterns of dysmorphogenesis; the long-term aim is to prevent the maternal and fetal damage. We work with animal models *in vivo*, and *in vitro* culture of whole embryos, embryonic tissues and embryonic cells.


Diabetes in the pregnant women is associated with an increased risk for malformations in the offspring and preeclampsia in the mother. We have studied the mechanisms behind the disturbed development of the offspring in animal models, embryo culture, as well as by *in vitro* culture of embryonic tissues and cells. In earlier work, we reported the occurrence of oxidative stress in embryos exposed to a diabetic environment. We have been able to block the diabetes-induced damage to the embryo and fetus by several agents, such as arachidonic acid, inositol, N-acetylcysteine, BHT, vitamin E and C, and folic acid. We have also started to investigate the importance of genetic predisposition for the development of malformations, a project, which is currently yielding data regarding the importance of the maternal and fetal genomes and epigenomes for the development of fetal dysmorphogenesis in diabetic pregnancy.

We have identified one gene, Glutathione Peroxidase-1, which is underexpressed in malformed offspring of diabetic rats (compared with non-malformed offspring of same litter), and its gene product, the antioxidative enzyme Gpx-1, is less distributed in the embryonic tissues, and its enzymatic activity markedly decreased. These findings can be related to the enhanced oxidative stress involved in the embryo-fetal dysmorphogenesis of diabetic pregnancy.


Recently we have found evidence for a new teratological pathway in diabetic pregnancy, activation of the receptor for advanced glycation end products (RAGE). We will pursue this line of research by identifying the ligand(s) causing the RAGE activation, and by investigating the possible therapeutical effects of blocking the RAGE response in embryos exposed to a diabetic environment.



Fetuses with facial malformation (left) and normal morphology (right), from diabetic rats.



Decreased expression of Gpx-1 in malformed compared to non-malformed offspring of diabetic rats.




Obesity in the pregnant woman is associated with increased risk for congenital malformations, in particular the risk for neural tube defects and cardiac malformations been found to be increased. We are currently involved in creating an animal model for this type of pregnancy, as well as attempting to affect embryonic development *in vitro* by

subjecting the embryos from control rats to serum from either control or high-fat diet rats in whole embryo culture for 48 hours. We found increased incidence of growth retardation and malformations in the embryos cultured in serum from hig-fat diet rats.



Rat fetus lacking tail, from obese mother

Intake of ethanol during pregnancy can harm the offspring; the risk increases with increased consumption. We have studied this situation, and attempted to alter the maternal defense against free oxygen radicals *in vivo* and *in vitro*, in order to diminish the ethanol-induced damage. We are studying possible biomarkers for maternal ethanol intake, by investigating embryonic tissues exposed to ethanol.



We are currently conducting a collaborative study on the dietary habits during pregnancy of women who have given birth to a child with Attention-Deficit/Hyperactivity Disorder.

Members of the group

Ulf Eriksson, professor

Parri Wentzel, associate professor

Andreas Ejdesjö, postdoc

Collaborators

Peter Nawroth, professor

Heidelberg, Germany

Emilio Herrera, professor

Madrid, Spain

Publications 2013-

1. Eriksson UJ, Wentzel P. [The status of diabetic embryopathy](#). Ups J Med Sci. **2016** Apr 27:1-17. [Epub ahead of print]
2. Ejdesjö A, Brings S, Fleming T, Fred RG, Nawroth PP, Eriksson UJ. [Receptor for advanced glycation end products \(RAGE\) knockout reduces fetal dysmorphogenesis in murine diabetic pregnancy](#). Reprod Toxicol. **2016** Apr 22;62:62-70.

Reviews 2013-

1. Fosterskadande effector av alkohol. Wentzel P & Eriksson UJ. Chapter 12, Beroendemedicin. Studentlitteratur, 2015
2. Post-implantation Diabetic Embryopathy. Eriksson UJ & Wentzel P, Chapter 41. Textbook of Diabetes and Pregnancy, Informa Healthcare, 2015

Agencies that support the work

The Novo Nordisk Foundation

The Swedish Diabetes Association

Stiftelsen Familjen Ernfors fond

Pathogenesis of type 1 Diabetes Mellitus

Stellan Sandler

The prevailing view is that an autoimmune reaction selectively destroys the insulin-producing β -cells in the pancreas in type 1 diabetes (T1DM). The aim of this project is to investigate cellular and molecular mechanisms involved in pancreatic β -cell damage and repair in this disease. We postulate that after certain types of damage β -cell function can be restored (Fig. 1). Furthermore, we believe that the β -cell is not a passive victim during a situation of potentially harmful exposure, but depending on gene expression and functional activity of the β -cell, the outcome can be affected. The aims of the present research projects are to investigate cellular and molecular mechanisms involved in pancreatic β -cell damage and repair in T1DM.




Fig. 1. Schematic view of the β -cell outcome following different immunologic or toxic assaults. In fetal and neonatal life, β -cell replication is increased, but later it becomes restricted. After birth β -cells acquire the full capacity to synthesise and release insulin (speckled symbols) upon appropriate stimuli. At one or several occasions in life, β -cells in some individuals are subject to damage (irregular arrows) which will lead to suppressed β -cell function and a reduction in insulin secretion. Depending on the genetic predisposition an autoimmune reaction will be launched which in certain individuals will cause extensive cell death leading to type 1 diabetes. In other individuals β -cells will survive, but their secretory function is impaired, which may have consequences for the glucose homeostasis. In some other individuals the β -cells may completely recover and the glucose tolerance will only be transiently disturbed. The latter outcome is most likely also dependent on genes regulating β -cell resistance to damage and β -cell repair.

Topics that are currently being investigated

- A. Characterization of the regulatory T cell response in diabetic mice
- B. Exploration of the bank vole as an animal model for human diabetes
- C. Antiviral intervention in NOD mice

Example of findings and hypothesis

Role of regulatory T-cells (T_{reg}) in T1DM (cf. topic A)




Fig. 2. Based of a number of different experiments we propse that Tregs in the multiple low dose streptozotocin (MLDSTZ) model of T1DM are functionally impaired, since a key cytokine (IL-35) is not being up-regulated in response to the proinflammatory environment induced by MLDSTZ.

Currently we are investigating the role of IL-35 in human T1DM. For instance we have found a correlation between remaining C-peptide levels in T1DM and IL-35. PhD student was awarded the Young Investigator Award from the Scandinavian Society for the Study of Diabetes in April 2016 for best published article year 2015 (reference #15 below).

Pancreatic islet in a diabetic bank vole




Fig. 3. Pancreatic islet of a female colonized bank vole 18 weeks of age. The bank vole was hyperglycemic (17.4 mM) 120 min after the IPGTT and serum insulin was elevated (2.34 mg/ml). The section was IHC stained with an Ljungan virus-specific antibody (brown colour) showing strong staining in some areas and weaker staining in the remaining area of the islet. Magnification 400X (cf Aim D above)

Significance

The aims of the present research projects are to investigate cellular and molecular mechanisms related to pancreatic β -cell damage and repair in T1DM, and in some cases probably also in T2DM. It is anticipated that a deeper knowledge of these issues will lead to new strategies for intervention in the autoimmune β -cell destructive processes, as well as novel methods to enhance β -cell resistance against direct cytotoxic damage. We hope that by studying cell signaling and the mechanisms leading to β -cell death, it will be able possible to elucidate which factors that are crucial for β -cell survival and possibly indentify candidate genes/proteins conferring β -cell susceptibility or resistance to destruction in T1DM.

Publications 2013-

8. Blixt M, Sandler S and Niklasson B.
Ljungan virus and diabetes
In: Diabetes and Viruses, Eds. Taylor K, Hyöty H, Toniolo A and Zuckerman AJ. Springer Science, New York. pp. 81-86, 2013 (ISBN 978-1-4614-4051-2)
9. Rydgren T, Öster E, Sandberg M and Sandler S.
Administration of IL-1 Trap prolongs survival of transplanted pancreatic islets to type 1 diabetic NOD mice.
Cytokine 63: 123-129, 2013
10. Chowdhury A, Dyachok O, Tengholm A, Sandler S and Bergsten S.

Functional changes between aggregated and dispersed insulin-producing cells.
Diabetologia 56: 1557-1568, 2013

11. Screiber O, Petersson J, Waldén T, Ahl D, Sandler S, Phillipson M and Holm L.
iNOS-dependent increase in colonic mucus thickness in DSS-colitic rats.
PLOS One 8: e71483, 2013
12. Singh K, Hjort M, Thorvaldson L and Sandler S.
Concomitant analysis of Helios and Neurolilin-1 as a marker to detect thymic derived regulatory T cells in naive mice.
Sci Rep 5, 7767; DOI 10.1038/srep07767 (2015)
13. Anvari, E., Wang X, Sandler S and Welsh N.
The H1-receptor antagonist cetirizine ameliorates high-fat-induced glucose intolerance in male C57BL/6 mice , but not diabetes outcome in female non-obese diabetic (NOD) mice.
Upsala J Med Sci 120: 40-46, 2015
14. Ludvigsen E, Carlsson C, Janson ET, Sandler S and Stridsberg M.
Somatostatin receptor 1-5 expression profiles during rat development.
Upsala J Med Sci 120: 157-168, 2015
15. Singh K, Kadesjö, E, Lindroos J, Hjort M, Lundberg M, Espes D,,CarlssonP-O, Sandler S* and Thorvaldson*. * Equal contribution to this work.
Interleukin-35 administration counteracts established murine type 1 diabetes – possible involvement of regulatory T-cell.
Sci. Rep. 5:12633, DOI: 10.1038/srep12633 pp. 1-19, 2015
16. Blixt M, Niklasson B and Sandler S.
Analysis of pancreatic islet morphology of diabetic bank voles revealed alterations seen in type 2 diabetes.
Submitted

Members of the research group

The following colleagues are engaged in the projects described above:

PhD Martin Blixt (adjunt, part-time research)

PhD (Lina Thorvalson (part time post-doc)

Laoratory technician IngBritt Hallgen (part-time)

PhD Student Kailash Singh

PhD student Gustaf Arbrant

Professor Stellan Sandler

Agencies that have supported the work

The Swedish Research Council

The European Foundation for the Study of Diabetes

The Swedish Diabetes Association

Barndiabetesfonden

Stiftelsen Familjen Ernfors fond


Role of tyrosine kinases in β -cell apoptosis and diabetes

Nils Welsh

It has recently been observed that patients suffering from both leukemia and diabetes were cured from not only leukemia, but also diabetes, when treated with the tyrosine kinase inhibitor Imatinib. (Veneri et al., N Engl J Med. 2005 352:1049-1050). An anti-diabetic action of Imatinib in Type 2 diabetes is further supported by our recent observation that Imatinib counteracts high-fat diet induced insulin resistance and hyperglycemia in rats (Hägerkvist et al., Clinical Science, (Lond). 2008 114(1):65-71). Moreover, in a study from 2009, Imatinib was also observed to induce remission of diabetes in db/db mice, possibly via decreasing insulin resistance and increasing the beta-cell mass (Han et al., Diabetes. 2009 58(2):329-3). Thus, in both animal models and in Type 2 diabetes patients Imatinib seems to improve glycemic control, possibly via an insulin sensitizing effect.

Imatinib appears to prevent and reverse not only Type 2 diabetes, but also diabetes of animal models with a Type 1 diabetes resembling disease. We have shown that Imatinib protects against beta-cell death in vitro and prevents diabetes in NOD mice and in streptozotocin-diabetic mice, both models for human beta-cell destruction and Type 1 diabetes (Hagerkvist et al., FASEB J. 2007 Feb;21(2):618-28, Hagerkvist et al., Cell Biol Int. 2006 30(12):1013-7). More recently, it has been observed by others that both Imatinib and Sunitinib not only prevented, but also reversed new-onset diabetes in NOD mice (Louvet et al., Proc Natl Acad Sci U S A. 2008 105(48):18895-900). Thus, there exists proof-of-principle in animal models for an anti-diabetic effect of Imatinib and similar tyrosine kinase inhibitors, and that a limited treatment period will not only reverse diabetes, but also mediate long-term protection against re-precipitation of the disease. This has led us (Mokhtari and Welsh, Clin Sci (Lond). 2009 118(4):241-7) and other investigators to propose clinical trials in which Imatinib is given to new-onset Type 1 diabetes patients.

The work by others and us indicates that Imatinib counteracts diabetes via different molecular mechanisms (Figure 1).



It appears that the four known targets of Imatinib, c-Abl, PDGFR, c-Kit and DDR1/2, may all play a role in the pathogenesis of diabetes. C-Abl is a proapoptotic tyrosine kinase that promotes beta-cell death when activated. Improper activation of the PDGF receptor has also been reported to occur in diabetes, and this may lead to increased insulin resistance of peripheral tissues. Activation of c-Kit and DDR1/2 is known to affect innate immunity, a component of the immune system that promotes inflammation and beta-cell dysfunction. Thus, it is conceivable that Imatinib, by targeting several pathways simultaneously, mediates a stronger antidiabetic effect than other drugs that affect only one particular pathway.

Figure 1 Possible mechanisms for the anti-diabetic effects of imatinib

Imatinib is known to inhibit the tyrosine kinases c-Abl, PDGFR, c-Kit and DDR1/2. Most likely, imatinib-induced protection against diabetes is mediated not by one single pathway, but via different molecular mechanisms. β -Cell survival is promoted by inhibition of c-Abl, which leads to decreased activation of the pro-apoptotic MAPK JNK and increased activation of the anti-apoptotic transcription factor NF- κ B. c-Abl inhibition might also lead to a dampened ER-stress response, via JNK or other pathways. Inhibition of PDGFR could contribute to decreasing peripheral insulin resistance and inflammatory processes, thereby promoting β -cell survival. Moreover, inhibition of c-Kit and DDR1/2 might also add to the anti-diabetic effects of imatinib, possibly by interfering with inflammatory responses.

It is the aim of this project to elucidate closer the mechanisms by which tyrosine kinases control beta-cell death and function. We are currently investigating Imatinib-mediated control of NF-kappaB, JNK, p38, PI3-kinase, SHIP2, PTEN, FAK, IRS1/2, beta-catenin, AKT and ERK signaling events. For this purpose insulin producing cells, either at basal conditions or under stress, are analyzed by immunoprecipitation, immunoblotting, confocal microscopy, real-time PCR, microarray analysis, flow cytometry and gel shift analysis. Cells are also genetically manipulated by lentiviral vectors to achieve up-or down-regulation of specific gene products. Signaling events will be correlated to beta-cell survival and function, as assessed by analysis of insulin production and apoptotic events. This will hopefully lead to a better understanding of the molecular events by which Imatinib protects against diabetes. Such improved knowledge may pave the way for a novel and improved treatment of diabetes.

Members of the group

Camilla Krishanovskii - Post-doc

Kyril Turpaev - Post-doc

Xuan Wang (part-time) – Post-doc

Andris Elksnis – Project student

Zhao, Lijun (part-time) - technician

Publications 2013-

1. D Mokhtari, A Al-Amin, K Turpaev, T Li, O Idevall-Hagren, J Li, A Wuttke, RG Fred, P Ravassard, R Scharfmann, A Tengholm, N Welsh. Imatinib mesylate-induced phosphatidylinositol-3-kinase signaling and improved survival in insulin-producing cells: Role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl. *Diabetologia*. 2013 Jun;56(6):1327-38
2. Anongnad Ngamjariyawat, Kyril Turpaev, Svitlana Vasylovska, Elena N. Kozlova, Nils Welsh. Co-culture of neural crest stem cells (NCSC) and insulin producing beta-TC6 cells results in cadherin junctions and protection against cytokine-induced beta-cell death. *PLoS One* 2013 Apr 17;8(4):e61828. doi: 10.1371/journal.pone.0061828
3. Ebrahim Anvari, Nils Welsh. The H1-receptor antagonist cetirizine protects partially against cytokine- and hydrogen peroxide-induced beta-TC6 cell death in vitro. *Pancreas*. 2014 May;43(4):624-9
4. Xuan Wang, Lin Jiang, Ulla Engström, Adam Ameer, Ola Wallerman, Yu Qi, Leif Andersson and Nils Welsh The transcription factor ZBED6 exists in beta-cells as nuclear and cytoplasmic forms and affects gene expression, proliferation and cell death. *PNAS*, 2013 Oct 1;110(40):15997-6002. doi: 10.1073/pnas.1303625110
5. Lopes M, Kutlu B, Miani M, Bang-Berthelsen CH, Størling J, Pociot F, Goodman N, Hood L, Welsh N, Bontempi G, Eizirik DL. Temporal profiling of cytokine-induced genes in pancreatic β -cells by meta-analysis and network inference. *Genomics*. 2014 Jan 23. pii: S0888-7543(14)00006-8. doi: 10.1016/j.ygeno.2013.12.007.
9. Welsh N. Does the small tyrosine kinase inhibitor imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis? *Expert Opinion on Investigational Drugs*. 2012, 21(11):1743-50
10. Anvari E, Wang X, Sandler S, Welsh N. The H1-receptor antagonist cetirizine ameliorates high-fat diet-induced glucose intolerance in male C57BL/6 mice, but not diabetes outcome in female non-obese diabetic (NOD) mice. *Ups J Med Sci*. 2014 Oct 7:1-7.
11. Wang X, Welsh N. Bcl-2 maintains the mitochondrial membrane potential, but fails to affect production of reactive oxygen species and endoplasmic reticulum stress, in sodium palmitate-induced β -cell death. *Ups J Med Sci*. 2014 Nov;119(4):306-15.
12. Fred RG, Boddeti SK, Lundberg M, Welsh N. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells. *Clin Sci (Lond)*. 2015 Jan;128(1):17-28.
13. Turpaev K, Welsh N. Brusatol inhibits the response of cultured beta-cells to pro-inflammatory cytokines in vitro. *Biochem Biophys Res Commun*. 2015 Mar 28. pii: S0006-291X(15)00590-2. doi: 10.1016/j.bbrc.2015.03.124
14. Anvari E, Wikström P, Walum E, Welsh N. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. *Free Radic Res*. 2015 Aug 14:1-11.

15. Fred RG, Kappe C, Ameer A, Cen J, Bergsten P, Ravassard P, Scharfmann R, Welsh N. Role of the AMP kinase in cytokine-induced human EndoC- β H1 cell death. *Mol Cell Endocrinol*. 2015 Jul 26;414:53-63.
16. Zang G, Sandberg M, Carlsson PO, Welsh N, Jansson L, Barbu A. Activated pancreatic stellate cells can impair pancreatic islet function in mice. *Ups J Med Sci*. 2015 Aug;120(3):169-80.
17. Wang X, Xie B, Qi Y, Wallerman O, Vasylovska S, Andersson L, Kozlova EN, Welsh N. Knock-down of ZBED6 in insulin-producing cells promotes N-cadherin junctions between beta-cells and neural crest stem cells in vitro. *Sci Rep*. 2016 Jan 11;6:19006.
18. Aileen King, Peter Jones, Shanta Persaud, Lisa Griffiths, Simon Howell, Nils Welsh. Imatinib prevents beta cell death in vitro but does not improve islet transplantation outcome. *Uppsala Journal of Medical Science*. In press.
19. Kyril Turpaev and Nils Welsh. Aromatic malononitriles stimulate the resistance of insulin-producing β TC6 cells to oxidants and inflammatory cytokines. *European Journal of Pharmacology*, in press.

Agencies that support the work

The Swedish Diabetes Association

Stiftelsen Familjen Ernfors Fond


Diabetes Wellness

EXODIAB

Intrarenal Hyaluronan in the Regulation of Fluid Balance. Pathophysiological Relevance to Renal Damage during Diabetes and Ischemia-Reperfusion.

Peter Hansell

The kidney is a main determinant of fluid/electrolyte balance and of mean arterial blood pressure. Hypertension is often caused by a renal inability to regulate fluid balance. The present research focuses on a matrix component (hyaluronan, HA) with extreme water attracting properties in the regulation of fluid balance. The



Histochemical staining for HA demonstrating the absence of HA in the normal renal cortex of rats (left). Patchy accumulation of interstitial HA in the ischemia-reperfusion damaged renal cortex (middle). Accumulated HA is found mainly in the same areas as infiltrating immune competent cells, as seen by parallel staining with haematoxylin-eosin (right).

proinflammatory property of HA is also evaluated in pathophysiological models. In contrast to the renal cortex which is almost void of HA, the interstitium of the renal medulla contains high amounts of HA during normal physiological conditions which changes depending on the body hydration status and, more severely, during pathological conditions.

We have found that HA has an important dynamic role in normal renal water-handling (hydration/dehydration) and that the intrarenal distribution of HA is severely altered during diabetes and after ischemia-reperfusion injury which correlates to renal dysfunction and inflammation. We have also demonstrated that the normal intrarenal distribution of HA is severely altered if angiotensin II tonus is diminished neonatally (during nephrogenesis) in the rat which correlates to renal dysfunction and inflammation. We aim to: a) determine the physiological relevance of the glycosaminoglycan hyaluronan (HA) in the regulation of renal fluid/electrolyte balance; b) determine the pathophysiological relevance of HA in the renal dysfunction during diabetes (diabetic nephropathy) and after ischemia-reperfusion injury; c) determine if hyaluronidase-treatment and siRNA improves renal function during diabetic nephropathy and following renal ischemia-reperfusion; d) elucidate the time frame and mechanisms in the development of the intrarenal heterogeneous distribution of HA which occur neonatally in the rat and its angiotensin II dependency.

Both in vivo and in vitro experiments are performed. Diabetes, ischemia, hydration, dehydration, hormones, pharmacological and biomolecular intervention activate/deactivate the systems. Human renal tissue from resections is also analysed. Rats and genetically modified mice are used during in vivo conditions whereafter the renal tissue is analysed using molecular biology to follow HA (amount, size), HA synthases, hyaluronidases and CD44 expression. Renomedullary interstitial cells in culture are used in parallel to follow similar parameters during interventions. In cooperation with the section of diagnostic radiology (assoc prof Per Liss) the mechanisms underlying diabetic nephropathy is to be validated and the increased sensitivity of the diabetic kidney to radiological contrast agents is elucidated. Cardiovascular disease is a dominant cause for invalidity and mortality. The results of the present projects may give rise to basic understanding of, and new treatment modalities in, fluid balance disorders and cardiovascular diseases.

Members of the group

Peter Hansell – Professor

Angelica Fasching - Laboratory Engineer

Fredrik Palm – Professor

Per Liss – Assoc Professor

Publications 2013-

1. Liss P, Hansell P, Fasching A & Palm F. Iodinated contrast media inhibit oxygen consumption in freshly isolated proximal tubular cells from elderly humans and diabetic rats: Influence of nitric oxide. *UJMS* 2016 Mar;121(1):12-6.
2. Persson P, Friederich-Persson M, Fasching A, Hansell P & Palm F. Adenosine A2a receptor stimulation prevents proteinuria in diabetic rats by promoting an anti-inflammatory phenotype without affecting oxidative stress. *Acta Physiol (Oxf)* 2015. Jul;214(3):311-8.
3. Stridh S, Palm F, Takahashi T, Ikegami-Kawai M & Hansell P. Inhibition of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronan. *UJMS* 2015. Nov;120(4):233-40

4. Hansell P & Palm F. A role for the extracellular matrix component hyaluronan in kidney dysfunction during ACE inhibitor fetopathy. *Acta Physiol (Oxf)*. 2015 Apr;213(4):795-804.
5. Do L, Dahl C, Kerje C, Hansell P, Mörner Ss, Lindqvist U, Engström-Laurent A, Larsson G & Hellman U. Estimation of hyaluronan molecular weight distribution in small biological samples with gas-phase electrophoretic mobility molecular analysis. *Intern J Cell Biol*. 2015;2015:938013, pp 1-5.
6. Nordquist L, Friederich-Persson M, Fasching A, Liss P, Shoji K, Nangaku M, Hansell P & Palm F. Activation of Hypoxia-Inducible Factors prevents diabetic nephropathy in rats. *J Am Soc Nephrol* 2015 Feb;26(2):328-38.
7. Persson P, Hansell P & Palm F. Reduced adenosine A2a receptor-mediated efferent arteriolar vasodilation contributes to diabetes-induced glomerular hyperfiltration. *Kidney Int* 2015 Jan;87(1):109-15.
8. Persson P, Fasching A, Teerlink T, Hansell P & Palm P. L-Citrulline, but not L-Arginine, prevents diabetes mellitus-induced glomerular hyperfiltration and proteinuria in rat. *Hypertension* 2014 Aug;64(2):323-9
9. Franzén S, Friederich-Persson M, Fasching A, Hansell P, Nangaku M & Palm F. Differences in susceptibility to develop parameters of diabetic nephropathy in four mouse strains with type 1 diabetes. *Am J Physiol Renal Physiol*. 2014 May 15;306(10):F1171-8.
10. Friederich-Persson M, Thörn E, Hansell P, Nangaku M, Levin M & Palm F. Kidney Hypoxia, Attributable to Increased Oxygen Consumption, Induces Nephropathy Independently of Hyperglycemia and Oxidative Stress. *Hypertension* 2013 Nov;62(5):914-9.
11. Hansell P, Welch WJ, Blantz RC & Palm F. Determinants of kidney oxygen consumption and their relation to tissue oxygen tension in diabetes and hypertension. *Clin Exp Physiol Pharmacol* 2013; 40: 123-137.
12. Hansell P. Editorial: NADPH-oxidase driven oxidative stress during experimental diabetes offsets NO-mediated regulation of renal medullary sodium transport. A potential treatment modality during type 1 diabetes? *Acta Physiol (Oxf)* 2013 Oct;209(2):94.
13. Nordquist L, Liss P, Fasching A, Hansell P & Palm F. Hypoxia in the diabetic kidney is independent of advanced glycation end-products. *Adv Exp Biol Med* 2013;765:185-193.
14. Persson P, Hansell P & Palm F. Adenosine A2 receptor-mediated regulation of renal hemodynamics and glomerular filtration rate is abolished in diabetes. *Adv Exp Biol Med* 2013;765:225-230.
15. Friederich-Persson M, Persson P, Fasching A, Hansell P, Nordquist L, Palm F. Increased kidney metabolism as a pathway to kidney tissue hypoxia and damage: effects of triiodothyronine and dinitrophenol in normoglycemic rats. *Adv Exp Med Biol*. 2013;789:9-14.
16. Stridh S, Palm F & Hansell P. Inhibition of hyaluronan synthesis in rats reduces renal ability to excrete fluid and electrolytes during acute hydration. *UJMS* 2013 Nov;118(4):217-221.
17. Eckerbom P, Hansell P, Bjerner T, Palm F, Weis J, Liss P. Intravoxel incoherent motion MR imaging of the kidney. Preliminary results. *Adv Exp Biol Med* 2013;765:55-58.

Renal Physiology

A. Erik Persson

The renal control of excretion is essential for fluid balance and blood pressure. One factor of great importance in regulation of fluid excretion is the tubuloglomerular feedback (TGF) control mechanism in the juxtaglomerular apparatus (Fig1). The macula densa cells in the distal part of the nephron senses the fluid flow rate. This information is used to activate the extraglomerular mesangial cells that modulate the response via influences from both hormones and fluid volume balance factors. Activation of the TGF mechanism finally leads to a contraction of the afferent arteriole. Renal renin release from the granular cells of the juxtaglomerular apparatus is controlled via the same mechanism.




Figure 1. Schematic illustration of the juxtaglomerular apparatus (JGA) with the macula densa cells in wall of the distal tubule and the glomerular arterioles.

Our group studies how hormones and other factors, e.g. nerves and NO, influence the overall function of the TGF mechanism and renin release using micropuncture techniques. We also employ isolated perfused tubule and arteriole techniques using fluorophores and digital imaging methods to determine calcium, chloride and NO in the macula densa cells and in the arteriolar smooth muscle cells. NO is also measured via microelectrodes. These techniques are used to investigate the sensing step in the TGF, the modulation step in the mesangial cells and the calcium release and contractile response of the arterioles. The juxtamedullary nephron preparation is used to visualise afferent arteriolar endothelial cells to measure calcium and NO. Our studies aim at understanding how the TGF mechanism and renin release operates, the effect of renal oxidative stress, NO and nerves on kidney function and to find the mechanism responsible for development of arterial hypertension.

Arterial hypertension is one of the most important health problems in the Western world and an important risk factor for cardio-vascular disease (CVD) and stroke. Unfortunately, these risk factors are only partly reduced during treatment with the existing drugs. Patients with treatment for hypertension have a reduced risk for stroke of about 50 % but still a 5 times higher risk than those without hypertension. The risk for CVD is only reduced 15 % with treatment and there is a 6-7 times higher risk for CVD compared to individuals without increase in blood pressure. Therefore it is important to further investigate how hypertension develops and find new and effective principles to prevent and treat the disease. Reduction of renal oxidative stress may increase nitric oxide (NO) bioavailability and thereby play an important role in preventing and/or treating CVD. To investigate the potential roles of oxidative stress and NO-deficiency in the development of CVD. Treatment modalities that reduce oxidative stress and/or increase NO-bioavailability will be assessed in both experimental models and clinical trials in order to find new and more efficient ways to treat or prevent CVD.

We have advanced equipment for investigating renal and cardiovascular function, and imaging systems for measuring oxidative stress and NO production (in vivo and in vitro). In

collaborations with physicians at different hospitals we have clinical trials to investigate the potential role of oxidative stress and NO-deficiency in CVD. In our experimental and clinical studies we aim to further investigate the link between renal and cardiovascular dysfunction, and to explore the potential benefits from reducing oxidative stress (e.g. antioxidant, nitroxide, low-sodium treatment) or increasing NO production (e.g. L-arginine or nitrate supplementation). The juxtaglomerular apparatus is a critical regulator of glomerular filtration rate, fluid excretion and renin release, factors that determine blood pressure. We believe that treatment strategies aiming to reduce oxidative stress and/or increase NO-bioavailability could be of great value in the future to treat hypertension to prevent stroke and cardio-vascular disease.

Members of the group

A. Erik Persson - Professor emeritus

Mattias Carlström - Researcher

Andreas Patzak - Guest researcher

Suênia Sampaio-Guest resercher

Gau Xian – Post doc

Ammar Farman - Graduate student

Peter Flacker- Graduate student

Zheng Bing Zhuge-Graduate student

Josiane de Campos Cruz-post doc

Publications 2013-

1. Carlström M, Brown RD, Yang T, Hezel M, Larsson E, Scheffer PG, Teerlink T, Lundberg JO, Persson AE; L-arginine or tempol supplementation improves renal and cardiovascular function in rats with reduced renal mass and chronic high salt intake. *Acta Physiol (Oxf)*. 2013 Apr;207(4):732-41. doi: 10.1111/apha.12079. Epub 2013 Feb 25.
2. Sällström J, Friden M; Simultaneous determination of renal plasma flow and glomerular filtration in conscious mice using dual bolus injection. *J Pharmacol Toxicol Methods J Pharmacol Toxicol Methods*. 2013 Jan 30;67(3):187-193.
3. Sällström J, Peuckert C, Gao X, Larsson E, Nilsson A, Jensen BL, Onozato ML, Persson AE, Kullander K, Carlstrom M. Impaired EphA4 signaling leads to congenital hydronephrosis, renal injury and hypertension. *Am J Physiol Renal Physiol*. 2013;1:305, F71-9.
4. Sällström J, Engström T, Fredholm BB, Persson AEG, Palm F. Inhibition of sodiumlinked glucose reabsorption in the kidney normalizes diabetes-induced glomerular hyper-filtration in conscious adenosine A1-receptor-deficient mice. *Acta Physiologica* 2013,
5. Persson AE, Lai EY, Gao X, Carlström M, Patzak A. Interactions between adenosine, angiotensin II and nitric oxide on the afferent arteriole. *Front Physiol* 2013, 18;4:187.
6. Carlström M, Liu M, Yang T, Zollbrecht C, Huang L, Peleli M, Borniquel S, Kishikawa H, Hezel M, Persson AE, Weitzberg E, Lundberg JO. Cross-talk between Nitrate-nitrite and NO synthase pathways in the control of vascular NO homeostasis. *Antioxid Redox Signal*, 2014, Feb 6.
7. Gao X, Janson L, Persson AE, Sandberg . Short-term glucosamine infusion increases islet blood flow in anaesthetized rats. *Islets* 2013, Nov 25
8. Lai E, Pettersson U, Verdugo AD, Carlsson PO, Bodin B, Källskog Ö, Persson AE, Sandberg M, Jansson L. Blood lipids affect rat islet blood flow regulation through β_3 adrenoreceptors. *Am J PhysiolEndocrinol Metab* 2014, 307, E653-63

9. Gao X, Peleli M, Zollbrecht C, Patzak A, Persson AE, Carlström M. Adenosine A1 receptor dependent and independent pathways in modulating renal vascular responses to angiotensin II. *Acta Physiol* 2015, 213:268-76.
10. Gao X, Yang T, Liu M, Peleli M, Zollbrecht C, Weitzberg E, Lundberg JO, Carlström M. NADPH oxidase in the renal microvasculature is a primary target for blood pressure –lowering effects by inorganic nitrate and nitrite. *Hypertension* 2015, 65:161-170.
11. Persson AE, Carlström M. Renal purinergic signalling in health and disease. *Acta Physiol* 2015, 213:805-07
12. Al-Mashhadi A, Neveus T, Stenberg A, Karanikas B, Persson AE, Carlström M, Wåhlin N. *J Pediatr Urol* 2015, 11:1-6
13. Yang T, Gao X, Sandberg M, Zollbrecht C, Zhang XM, Hezel M, Liu M, Peleli M, Lai EY, Harris RA, Persson AE, Fredholm BB, Jansson L, Carlström M. *Diabetologica* 2015, 58:1610-20.
14. Turner AJ, Brown RD, Boyce A, Gibson KJ, Persson AE. Fetal tubuloglomerular feedback in an ovine model of mild maternal renal disease. *Physiol Rep* 2015, 3
15. Peleli M, Hezel M, Zollbrecht C, Persson AE, Lundberg JO, Weitzberg E, Fredholm BB, Carlström M. *Front Physiol* 2015, 7:6:222.

Dissertation examination

Xiang Gao: "Local purinergic control of arteriolar reactivity in pancreatic islets and renal glomeruli" October 2014

Agencies that support the work

The Swedish Research Council

STINT

Gastro-intestinal protection mechanisms studied in vivo

Lena Holm

During homeostasis, the colonic mucus successfully separates the vast luminal microbiota from the single epithelial cell layer and resident immune cells of the mucosa. When this barrier fails, colitis is established. Our research focuses on **the interplay between the commensal microbiota, administered probiotics and the colonic mucosal barrier in health and during colitis**, with special emphasis on the underlying mechanisms of colitis induction and probiotic protection. We have developed an animal model allowing

direct access to the colonic mucosa with **intravital microscopy**, and the majority of our experiments include *in vivo* studies of the mucus layers (Fig. 1), epithelium, immune cells and blood flow. During the last years we have extensively increased our possibilities to perform high-resolution longitudinal *in vivo* studies of interactions of the microbiota/probiotics/mucus with the epithelium and immune cells in real-time by adapting our *in vivo* model to high-speed





Fig 1. The mucus layers in different parts of the GI tract

confocal microscopy available in our lab (Fig.2). Furthermore, with a newly installed Laser Speckle Contrast Analysis setup, blood flow of colitic and healthy parts of the colon will be performed.

Fig.2



The influence of pre- and pro-biotics on mucus dynamics, bacterial composition, inflammatory variables and epithelial tight junctions are studied to elucidate the mechanisms behind their protective effects (Fig. 3). We have shown that pretreatment with **probiotics** (*L. reuteri*)




Fig 3. 3D-visualization of capillaries (stained with CD31: red) surrounding colonic crypts just below the luminal epithelial layer (tight junctions stained with ZO-1: green).

prevent DSS-induced colitis in rats and mice. Up regulation of P-selectin in the colonic venules was prevented by probiotic therapy, and in vivo fluorescence microscopy confirmed these results by showing decreased leukocyte rolling and adhesion to endothelial cells, as well as decreased platelet-endothelial cell interactions. There are no intestinal *in vitro* culture systems that replicate the complexity of the secreted mucus barrier. However, our *in vivo* model uniquely enables reliable measurements of thickness and permeability of the mucus barrier. Using this model we have demonstrated that the adherent gastric and colonic mucus gel in vivo can be divided in two layers, a firmly and a loosely adherent layer (Fig 1). The firmly adherent mucus layer acts as a barrier towards hydrochloric acid in the stomach and luminal bacteria in the colon. In addition to the barrier function of the firm mucus resulting in significantly lower number of bacteria than in the loosely adherent mucus (1/10), we found that the composition of the

microbiota differed substantially between the two layers. The difference in bacterial numbers and composition was completely eradicated in DSS-induced colitic rats, where high levels of translocated bacteria were found in the mesenteric lymph nodes. Interestingly, pretreatment with *L. reuteri* (cocktail of 4 strains) prevented bacterial translocation and colonic inflammation but did not influence on the distorted mucus microbiota. Furthermore, we showed

that each of two different *L. reuteri* strains protected mice against DSS-induced colitis. Mechanisms behind this protection involved increased firmly adherent mucus thickness and tight junction expression. We have also constructed luminescent and fluorescent *L. reuteri* R2LC, which will provide useful tools for future *in vivo* studies of interactions between the bacteria and the host.

We have shown that dietary nitrate induces potent protection against NSAID induced upper GI inflammation. Bacteria in the oral cavity reduce nitrate to nitrite, which is further reduced to nitric oxide, NO, in the acidic stomach. NO strengthen the mucosal barrier by increasing mucus thickness and blood flow. We have, however, also shown protection by dietary nitrate even further down in the intestine where luminal NO is not increased. Leukocyte recruitment in response to proinflammatory chemokine and NSAID was decreased. Despite attenuation of the acute immune response, the overall ability to clear a bacterial infection was not suppressed.

Members of the group

Lena Holm, professor

David Ahl, PhD student

Annika Jägare, laboratory engineer

Shokoufeh Karimi, PhD student*

Haoyu Liu, PhD, post doc

Richard Shore, PhD student**

Tomas Waldén, PhD, post doc

* Shared affiliation with the Department of Microbiology, SLU, Uppsala

** Shared affiliation with the Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm

Publications 2013-

1. G Jakobsdottir, C Jädert, L Holm, M E. Nyman. Propionic and butyric acids, formed in caecum of rats fed highly fermentable dietary fibre, are reflected in portal and aortic serum. *Br J Nutr.* 2013 Nov 14;110(9):1565-72. doi: 10.1017/S0007114513000809. Epub: 26 March 2013. PMID: 23531375
2. O. Schreiber, J. Petersson, T. Waldén, D Ahl, S. Sandler, M. Phillipson and L. Holm. iNOS-dependent increase in colonic mucus thickness in DSS-colitic rats. *PLoS ONE* 2013 8(8): e71843. doi:10.1371/journal.pone.0071843
3. C Jädert, M Phillipson, L Holm, JO Lundberg, S Borniquel. Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease. *Redox Biol.* 2013 Dec 24;2:73-81. doi: 10.1016/j.redox.2013.12.012. eCollection 2014. PMID: 24494186 [PubMed]
4. Kober, D Ahl, L Holm, SR Carding, N Juge . $\gamma\delta$ T-cell-deficient mice show alterations in mucin expression, glycosylation and goblet cells but maintain an intact mucus layer. *Am J Physiol Gastrointest Liver Physiol.* 2014 Feb 6. [Epub ahead of print]
5. Petersson J, Jädert C, Phillipson M, Borniquel S, Lundberg JO, **Holm L.** Physiological recycling of endogenous nitrate by oral bacteria regulates gastric mucus thickness. *Free Radic Biol Med.* 2015 Dec;89:241-7. doi:

10.1016/j.freeradbiomed.2015.07.003. Epub 2015 Jul 8. PMID: 26163002

6. Ahl D, Liu H, Schreiber O, Roos S, Phillipson M, **Holm L**. [Lactobacillus reuteri increases mucus thickness and ameliorates DSS-induced colitis in mice](#). *Acta Physiol (Oxf)*. 2016 Apr 20. doi: 10.1111/apha.12695. [Epub ahead of print] PMID: 27096537
7. Karimi S, Ahl D, Vågesjö E, **Holm L**, Phillipson M, Jonsson H, Roos S. [In Vivo and In Vitro Detection of Luminescent and Fluorescent Lactobacillus reuteri and Application of Red Fluorescent mCherry for Assessing Plasmid Persistence](#). *PLoS One*. 2016 Mar 22;11(3):e0151969. doi: 10.1371/journal.pone.0151969. eCollection 2016. PMID: 27002525

Book Chapter.

1. Granger DN, **Holm L**, Kvietys P. [The Gastrointestinal Circulation: Physiology and Pathophysiology](#). *Compr Physiol*. 2015 Jul 1;5(3):1541-83. doi: 10.1002/cphy.c150007. Review. PMID: 26140727

Agencies that support the work

The Swedish Research Council


Formas (The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning)

BioGaia AB

Targeting leukocytes in health and disease

Mia Phillipson


The capacity of circulating leukocytes to arrest on the surface of inflamed endothelium, transmigrate, and penetrate into the underlying tissue are key steps in response to infections as well as other inflammatory processes. The importance of recruited as well as tissue resident leukocytes also during homeostasis, angiogenesis and tumor growth is increasingly being acknowledged. Expanding the knowledge of the mechanisms that regulate the recruitment and actions of leukocytes is very important to be able to control and eventually limit inflammatory response, tumor growth and tissue damage.



A venule (anti-CD31, red) with emigrated neutrophils (anti-Gr1, green).

The overall aim of the research conducted in my laboratory is to uncover novel roles of leukocytes and to find means to regulate their specific functions in settings spanning from organ development to tissue healing, angiogenesis and inflammation. By employing state of the art techniques for studies of leukocyte trafficking and interactions *in vivo* (high speed confocal microscopy), we are delineating how leukocytes are recruited to sites of inflammation or hypoxia as well as their effector functions in tissue. The signals and chemokines initiating

leukocyte recruitment as well as the adhesion molecules involved in the different steps of the leukocyte recruitment cascade are being investigated. We have established a new step in the leukocyte recruitment cascade, intravascular crawling, and study how chemokines are transported into the inflamed venules. We recently found that chemokines sequestered on endothelial heparan sulphate direct crawling leukocytes towards optimal sites for transmigration (Massena et al., Blood, 2010). We also investigate how the intestine can withstand the constant pressure of the commensal bacterial flora without developing inflammation, and are presently mapping the role, behaviour and interactions of different intestinal leukocytes during homeostasis as well as colitis.



The reestablished glomeruli-like islet vasculature surrounded by muscle blood vessels two weeks after transplantation to striated mouse muscle

In addition, we recently identified a clinically relevant and attractive approach of curing type 1 diabetes, since islets transplanted to muscle became fully revascularized and therefore functioned better compared to islets implanted in the liver (Christoffersson et al., Diabetes, 2010), the organ traditionally used for islet transplantation. Means to limit the immunosuppressing therapies required following allogeneic islet transplantations have also been investigated (Vågesjö et al. Cell Transplantation, 2015). A specific neutrophil subtype with pro-angiogenic features was recently demonstrated in the circulation, and was found to be recruited to sites of hypoxia by Vascular Endothelial Growth Factor A (VEGF-A) (Christoffersson et al., Blood, 2012, Massena et al., Blood, 2015). We currently aim to accelerate angiogenesis and wound healing by affecting the microenvironment to induce specific leukocytes recruitment as well as

Members of the group

Mia Phillipson - Professor

David Ahl – PhD student

Antoine Giraud – Research Engineer

Jalal Haft – PhD student

Carmen Herrera Hidalgo – PhD student

Haoyu Liu – post doc

Sara Massena Santos – PhD student

John Sedin – Post Doc

Cédric Seigneiz – Post Doc

Evelina Vågesjö – PhD student

Tomas Waldén – Post Doc

Publications 2013-

1. S Massena*, G Christoffersson*, E Vågesjö*, C Seigneiz, K Gustafsson, F Binet, C Herrera Hidalgo, A Giraud, J Lomei, S Weström, M Shibuya, L Claesson-Welsh, P

- Gerwins, M Welsh, J Kreuger, **M Phillipson**. Identification and characterization of VEGF-A-responsive neutrophils expressing VEGFR1, CD49d and CXCR4 in mice and humans. *Blood*, 126: 2016-2026, 2015. Commentary accompanying this article: Hypoxia-recruited angiogenic neutrophils. EL CAMPBELL. *Blood*, 126, 1972-1973, 2015
2. M Nikpour, K Gustafsson, E Vågesjö, C Seignez, A Giraud, **M Phillipson**, M Welsh. Shb deficiency in endothelium but not in leukocytes is responsible for impaired vascular performance during hindlimb ischemia. *Acta Physiologica*, 214: 200-209, 2015.
 3. J Petersson*, C Jädert*, **M Phillipson**, S Borniquel, JO Lundberg, L Holm. Physiological recycling of endogenous nitrate by oral bacteria regulates gastric mucus thickness. *Free Radic Biol Med*. 89: 241-247, 2015.
 4. G Christoffersson, T Waldén, M Sandberg, G Opdenakker, PO* Carlsson **M Phillipson** M. Matrix metalloproteinase-9 is essential for physiological beta cell function and islet vascularization in adult mice. * Shared contribution as last author *Am J Pathol* 185:1094-1103, 2015.
 5. E Vågesjö, G Christoffersson, TB Walden, PO Carlsson, M Essand, O Korsgren, **M Phillipson**. Immunological shielding by induced recruitment of regulatory T lymphocytes postpones rejection of transplanted pancreatic islets. *Cell Transplant*, 24:263-276, 2015.
 6. G Christoffersson, E Vågesjö, S Massena US Pettersson, EK Nilsson, JE Broman, HB Schiöth, C Benedict, **M Phillipson**. Acute sleep deprivation impairs neutrophil mobilization, populations and function in healthy young men. *Brain, Behavior and Immunity*, 41: 162-72, 2014.
 7. S Li, US Pettersson, B Hoorelbeke, K Schelfhout, E Martens, J Balzarini, J Van Damme, **M Phillipson**, G Opdenakker. Chlorite-oxidized oxyamylose (COAM): mouse chemokine-binding and -inducing properties and molecular probe for in vivo chemotaxis. *PLoS One*, 9:e104107, 2014.
 8. LC Dieterich, P Schiller, S Massena, **M Phillipson**, A Dimberg. Regulation of alphaB-crystallin in tumor angiogenesis and regulation of the tumor microenvironment. *Angiogenesis*, 16: 975-83, 2013.
 9. C Jädert, **M Phillipson**, L Holm, JO Lundberg, S Borniquel. Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease. *Redox Biol*, 2: 73-81, 2013.
 10. O Schreiber, J Petersson, A Jägar, S Sandler, JO Lundberg, **M Phillipson**, L Holm. iNOS-dependent increase in colonic mucus thickness in DSS-colitic rats. *PLoS One*, 8:e71843, 2013.
 11. C Benedict, J Cedernaes, V Giedraitis, E Nilsson, PS Hogenkamp, E Vågesjö, US Pettersson, S Massena, G Christoffersson, **M Phillipson**, JE Broman, L Lannfelt, H Zetterberg, HB Schiöth. Acute sleep deprivation increases serum levels of neuron-specific enolase (NSE) and S-100 calcium binding protein B (S100B) in healthy young men. *Sleep*, 37:195-8, 2013.

Reviews and book chapters 2013-

1. **Phillipson M**, Claesson-Welsh L, Welsh M. VEGFA-induced vascular permeability and leukocyte extravasation. Invited review in *Vascular Signaling in Health and Disease*, Drs Mirko HH Schmidt and Stefan Liebner, Springer, 2013.

Dissertations

Sara Massena “A close-up on neutrophils: Visualizing the mechanisms of their in vivo recruitment and function” PhD December 2015

Gustaf Christoffersson "Leukocytes in Angiogenesis: Learning from Transplanted Pancreatic Islets" PhD April 2013

Agencies that support the work

Knut and Alice Wallenberg foundation

Ragnar Söderberg Foundation

Swedish Foundation for Strategic Research

Swedish Research Council

The Diabetes Wellness Foundation

The Ernfors family foundation

The Novo Nordic Foundation

The Swedish Diabetes Foundation

Vinnova

The research group also takes part of the strategic funding for Diabetes (*Excellence of diabetes research in Sweden; Exodiab*) shared between Lund and Uppsala Universities

Diabetic Nephropathy and Uremic Toxins

Fredrik Palm

Diabetic Nephropathy (core director: Fredrik Palm)

Diabetes mellitus is the most common cause for end-stage renal disease. The exact mechanisms mediating diabetes-induced kidney damage (diabetic nephropathy) are largely unknown despite intense research. The aim of this research program is to study effects of diabetes on renal metabolism and microcirculation in relation to functional changes. The ultimate goal is to find new treatment strategies to avoid the development of kidney dysfunction during diabetes.

We were the first laboratory to report kidney hypoxia in diabetes (Palm et al., *Diabetologia* 2003, 46(8):1153-1160) and this finding has recently been confirmed in diabetic patients with established nephropathy (Wang et al., *J Magnet Res Imag* 2011, 33(3):655-660). Since then, our work has focused on identifying the mechanisms resulting in the diabetes-induced kidney hypoxia. So far, we have identified several contributing mechanisms, including increased oxidative stress, altered red-ox balance, increased renal oxygen consumption and increased tubular electrolyte transport work due to both increased glomerular filtration, but also increased glucose transport in the proximal tubule. Recently we have made a very significant observation in rats treated with the mitochondrial uncoupler dinitrophenol for up to four weeks. These otherwise healthy rats displayed excessive oxygen utilization, due to the uncoupled mitochondria, and developed pronounced kidney hypoxia. Interestingly, these rats also displayed 50% increased urinary protein excretion, tubulointerstitial damage and infiltration of

immune cells. Therefore, we are the first to show that increased oxygen utilization is enough to cause kidney hypoxia and nephropathy. This is a major breakthrough since previous studies always have been associated with confounding factors, such as hyperglycemia, increased oxidative stress and altered tubular transport.




Figure 1. Activation of the hypoxic gene response by chronic CoCl₂ treatment prevented the diabetes-induced kidney hypoxia and the clinical signs of diabetic nephropathy, such as tubulointerstitial fibrosis, proteinuria and glomerular hyperfiltration.

We have also approached the problem with kidney hypoxia from another angle by chronically treating diabetic animals with CoCl₂, which activates the hypoxic gene response (HIF). The results demonstrate that HIF activation prevents the diabetes-induced kidney hypoxia and tubulointerstitial damage (Fig. 1 and 3).

Metabolic and functional alterations occurring in kidneys from diabetic animals (rats and genetically modified mice) are studied using *in vivo* techniques and molecular biology. Mitochondrial function and internal defence mechanisms are studied in diabetic animals and kidney tissue from diabetic patients. Renal blood flow and oxygen metabolism are studied using Magnetic Resonance Imaging (MRI) in animals as well as in diabetic patients.




Figure 2. Thirty minutes of warm ischemia to the left kidney (right kidney on the images) did not alter kidney function or the intrarenal blood flow (images above measured by computed tomography) in control rats four weeks after the ischemic insult. However, the same ischemic insult caused markedly reduced kidney function (glomerular filtration rate about 10% of normal), atrophy and hypoperfusion of the left kidney. Diabetic rats administered a bolus dose of C-peptide before the ischemic insults were protected against the increased susceptibility to the ischemia-reperfusion injury.




Figure 3. Summary of all investigated mechanisms affecting intrarenal oxygenation in diabetes. Tocopherol (vitamin E) is an antioxidant, AL1576 inhibits aldose reductase and presents activation of the polyol pathway, aminoguanidine inhibits AGE formation, L-NIL inhibits iNOS, STZ + Tx denotes animals administered streptozotocin (to induce diabetes) and 24h thereafter received enough islets of Langerhan's to reverse the hyperglycemia, CoCl₂ activates HIF and prevents kidney hypoxia if starting treatment early (preventive) but fails to reverse already established nephropathy (reversal), acute L-arginine administration induces NO release and partly restores kidney oxygenation, chronic dinitrophenol administration results in excessive oxygen utilization causing kidney hypoxia and clinical signs of nephropathy, siRNA directed against DDAH-2 reduced DDAH-2 protein expression by more than 60% but failed to normalize kidney oxygenation.

These non-invasive techniques were used in a recent study, in which we studied the effect of ischemia-reperfusion injury in diabetic kidneys (Fig. 2). It is well-known that diabetic kidneys are increasingly susceptible to an ischemic insult, but we were able to show that administration

of a bolus dose of C-peptide had pronounced renoprotective effects in diabetes. Interestingly, we have previously shown that C-peptide reduces oxygen utilization in the diabetic kidney and this might therefore explain the renoprotective effects against the ischemic insult in these kidneys. This finding might have important clinical implications since C-peptide is an endogenous substance, which therefore only needs relatively minor administrative work before moving into clinical practice.

By combining basic renal and diabetic research, we believe we can contribute to increase the understanding of the mechanisms involved in diabetic nephropathy, which will facilitate development of novel therapies. Additionally, metabolic alterations always precede histological changes, which potentially can be used as a clinical diagnostic tool when identifying patients at increased risk to develop diabetic nephropathy. This would hopefully enable early treatment modalities before the seemingly irreversible histological changes occur with manifest nephropathy.

Our results so far suggest:

- A) Diabetic rats display kidney hypoxia, which is linked to excessive oxygen utilization.
- B) Mitochondrial uncoupling results in excessive oxygen utilization and development of nephropathy.
- C) C-peptide protects the diabetic kidney against ischemic insults, which may in part be explained by the oxygen utilization-lowering effects of C-peptide in diabetes.
- D) By using non-invasive imaging techniques, we may be able to transfer our knowledge from our experimental settings into clinical use.
- E) Intrarenal hypoxia per se causes kidney disease.

Agencies that support the work

Swedish Research Council

Swedish Diabetes Association

Family Ernfors Foundation

Magnus Bergwall Foundation

Åke Wiberg Foundation

ERC Marie Curie IRSES

Uremic Toxins (core director: Lina Nordquist)

In uremic patients, losses of kidney function are accompanied by deteriorating organ function attributable to the accumulation of uremic retention solutes. Compounds that exert an adverse biologic impact are called uremic toxins

Indoxyl sulfate is a representative uremic toxin made by the liver from indole produced by gut bacteria from tryptophan. In addition to causing uremic symptoms, indoxyl sulphate per se accelerates the progression of renal failure. Our recent study for the first time demonstrated that indoxyl sulfate increases oxygen consumption and aggravates local hypoxia in renal tubular cells via enhancement of oxidative stress (Fig. 4). Uremic states per se may accelerate progression of renal dysfunction via aggravation of chronic hypoxia as a final common pathway to end stage renal disease.




Figure 4. Improvement of oxygenation of the remnant kidney by reduction of uremic toxins. (A) Immunohistochemical staining of pimonidazole accumulation in the cortex showed improvement of oxygenation of the remnant kidney in animals treated with the oral absorbent AST-120 that reduces plasma levels of indoxyl sulfate. No pimonidazole accumulation was observed in cortical tubules of normal animals. (B) Semi-quantitative analysis of pimonidazole accumulation confirmed better oxygenation of the remnant kidney in rats treated with AST-120. (C) Pimonidazole accumulation, an indicator of hypoxia, showed a good correlation with serum IS levels in RK rats.

Agencies that support the work

Swedish Society for Medical Research

Lars Hierta Foundation

Members of the group

Fredrik Palm, Ph.D.

Lina Nordquist, Ph.D., core director

Per Liss, MD, Ph.D., Associate professor

Angelica Fasching - research engineer

Susanne Karlsson – research engineer

Thomas Schiffer – Ph.D. Post Doc

Malou Friederich – Ph.D. Post Doc

Patrik Persson, Ph.D. Post Doc

Ebba Sivertsson, Ph.D.-student

Carla Carvalho, Ph.D.-student

Oskar Nensén, MD/Ph.D-student

Per Eckerbom, Ph.D.-student

Publications 2013-

7. Per Eckerbom, Peter Hansell, Tomas Bjerner, Fredrik Palm, Jan Weis and Per Liss. Intravoxel incoherent motion MR imaging of the kidney: Pilot study. *Adv Exp Med Biol* 2013, 765:55-58
8. Lina Nordquist, Per Liss, Angelica Fasching, Peter Hansell and Fredrik Palm. Hypoxia in the diabetic kidney is independent of advanced glycation end-products. *Adv Exp Med Biol* 2013, 765: 185-193
9. Malou Friederich Persson, William J. Welch, Christopher S. Wilcox and Fredrik Palm. Kidney function after in vivo gene silencing of Uncoupling Protein-2 in streptozotocin-induced diabetic rats. *Adv Exp Med Biol* 2013, 765:217-223
10. Patrik Persson, Peter Hansell and Fredrik Palm. Adenosine A2 receptor-mediated regulation of renal hemodynamics and glomerular filtration rate is abolished in diabetes. *Adv Exp Med Biol* 2013, 765:225-230
11. Christopher S. Wilcox, Fredrik Palm and William J. Welch. Renal oxygenation and function of the rat kidney: effects of inspired oxygen and preglomerular oxygen shunting. *Adv Exp Med Biol* 2013, 765:329-334
12. Daniela Patinha, Angelica Fasching, Dora Pinho, António Albino-Teixeira, Manuela Morato and Fredrik Palm. Angiotensin II contributes to glomerular hyperfiltration in diabetic rats independent of adenosine type 1 receptors. *Am J Physiol Renal Physiol* 2013, 304:F614-622.
13. Malou Friederich-Persson, Patrik Persson, Angelica Fasching, Peter Hansell, Lina Nordquist and Fredrik Palm. Increased kidney metabolism as a pathway to kidney tissue hypoxia: effects of triiodothyronine and dinitrophenol in normoglycemic rats. *Adv Exp Med Biol* 2013, 789:9-14.
14. Frank Helle, Trude Skogstrand, Idit F. Schwartz, Doron Schwartz, Bjarne M. Iversen, Fredrik Palm and Michael Hultström. Nitric oxide in afferent arterioles after uninephrectomy depends on extracellular L-arginine. *Am J Physiol Renal Physiol* 2013, 304:F1088-1098.
15. Peter Stenvinkel, Ole Frøbert, Björn Anderstam, Fredrik Palm, Monica Eriksson, Ann-Christin Bragfors-Helin, Abdel Rashid Qureshi, Tobias Larsson, Andrea Friebe, Andreas Zedrosser, Johan Josefsson, My Svensson, Berolla Sahdo, Lise Bankir and Richard J Johnson. Metabolic changes in summer active and anuric hibernating free-ranging Brown bears (*Ursus arctos*). *PLoS One* 2013, 8 (9):e72934.
16. Sara Stridh, Fredrik Palm and Peter Hansell. Inhibition of hyaluronan synthesis reduces renal ability to excrete fluid and electrolytes during acute hydration. *Uppsala J Med Sci* 2013, 118:217-221.
17. Malou Friederich-Persson, Erik Thörn, Peter Hansell, Masaomi Nangaku, Max Levin and Fredrik Palm. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. *Hypertension* 2013, 62(5):914-919.
18. Johan Sällström, Terese Engström, Bertil B. Fredholm, A. Erik G. Persson and Fredrik Palm. Inhibition of sodium-linked glucose reabsorption normalizes diabetes-induced

- glomerular hyperfiltration in conscious adenosine A1-receptor deficient mice. *Acta Physiol*, 2014, 210:440-445.
19. Stephanie Franzén, Liselotte Pihl, Nadeem Khan, Fredrik Palm and Håkan Gustavsson. Repetitive measurements of intrarenal oxygenation in vivo using L band electron paramagnetic resonance. *Adv Exp Med Biol* 2014, 812:135-141. PMID 24729225.
 20. Malou Friederich-Persson, William J. Welch, Zaiming, Luo, Fredrik Palm and Lina Nordquist. Angiotensin II reduces transport-dependent oxygen consumption, but increases transport-independent oxygen consumption in immortalized mouse proximal tubular cells. *Adv Exp Med Biol* 2014, 812:157-163. PMID 24729228.
 21. Christoffer Laustsen, Sara Lycke, Fredrik Palm, Jakob Appel Østergaard, Bo Martin Bibby, Rikke Nørregaard, Allan Flyvbjerg, Michael Pedersen, Jan Henrik Ardenkjær-Larsen. High altitude may alter oxygen availability and renal metabolism in diabetics as measured by hyperpolarized [1-13C]pyruvate magnetic resonance imaging. *Kidney Int* 2014, 86:67-74. PMID 24352155.
 22. Stephanie Franzén, Masaomi Nangaku, Peter Hansell and Fredrik Palm. Differences in susceptibility to develop parameters of diabetic nephropathy among four mouse models of type 1 diabetes. *Am J Physiol – Renal Physiol*, 2014, 306(10):F1171-1178. PMID: 24623147.
 23. Patrik Persson, Angelica Fasching, Tom Teerlink, Peter Hansell and Fredrik Palm. L-citrulline, but not L-arginine, prevents diabetes mellitus-induced glomerular hyperfiltration and proteinuria in rats. *Hypertension*, 2014, 64:323-329. PMID: 24866144.
 24. Christoffer Laustsen, Kasper Lipsø, Jakob Appel Østergaard, Rikke Nørregaard, Allan Flyvbjerg, Michael Pedersen, Fredrik Palm, Jan Henrik Ardenkjær-Larsen. Insufficient insulin administration to diabetic rats increases substrate utilization and maintains lactate production in the kidney. *Physiol Rep*, 2014, 2(12):e12233. PMID: 25501426.
 25. Andreea Barbu, Leif Jansson, Monica Sandberg, My Quach and Fredrik Palm. The use of hydrogen gas clearance for blood flow measurements in single endogenous and transplanted pancreatic islets. *Microvasc Res*, 2015, 97:124-129. PMID 25446368.
 26. Lina Nordquist, Angelica Fasching, Per Liss, Masaomi Nangaku, Peter Hansell and Fredrik Palm. Activation of Hypoxia-Inducible Factors prevents diabetic nephropathy in rats. *J Am Soc Nephrol*, 2015, 26(2):328-338. PMID: 25183809.
 27. Patrik Persson, Peter Hansell and Fredrik Palm. Reduced adenosine A2a receptor-mediated efferent arteriolar dilation causes diabetes-induced glomerular hyperfiltration. *Kidney Int*, 2015, 87(1):109-115. PMID: 24940797.
 28. Patrik Persson, Malou Friederich-Persson, Angelica Fasching, Peter Hansell and Fredrik Palm. Adenosine A2a receptor stimulation prevents proteinuria in diabetic rats by promoting an anti-inflammatory phenotype without affecting oxidative stress. *Acta Physiol (Oxf)*, 2015, 214(3):311-318. PMID: 25891445.
 29. Sara Stridh, Fredrik Palm, Tomoko Takahashi, Mayumi Ikegami-Kawai and Peter Hansell. Inhibition of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronan. *Ups J Med Sci*, 2015, 14:1-8. PMID: 26175092.
 30. Julie O'Neill, Angelica Fasching, Liselotte Pihl, Daniela Patinha, Stephanie Franzen and Fredrik Palm. Acute SGLT inhibition normalizes oxygen tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. *Am J Physiol Renal Physiol*, *Am J Physiol Renal* 2015, 309: F227–234. PMID: 26041448.
 31. Stephanie Franzén and Fredrik Palm. Endothelin type A receptor inhibition normalizes intrarenal hypoxia in diabetic rats by improving oxygen delivery. *Diabetologia*, 2015, 58(10):2435-2442. PMID: 26173672.

32. Jacqueline M Melville, Fredrik Palm and Michael Hultström. Renal oxygenation during haemorrhage is not aggravated by Angiotensin II AT1-receptor blockade. *Acta Physiol (Oxf)*. 2016, 216(2):153-155. PMID: 26300043.
33. Per Liss, Peter Hansell, Angelica Fasching and Fredrik Palm. Iodinated contrast media inhibit oxygen consumption in freshly isolated proximal tubular cells from elderly humans and diabetic rats: Influence of nitric oxide. *Ups J Med Sci*, 2016, 2:1-5. PMID: 26933994.
34. Stephanie Franzén, Liselotte Pihl, Nadeem Khan, Håkan Gustafsson and Fredrik Palm. Pronounced kidney hypoxia precedes albuminuria in type-1 diabetic mice. *Am J Physiol Renal Physiol*, in press. PMID: 26936871.

Reviews 2013-

2. Peter Hansell, William J. Welch, Roland C. Blantz and Fredrik Palm. Determinants of kidney oxygen consumption and its relation to tissue oxygen tension in diabetes and hypertension. *Clin Exp Pharmacol Physiol* 2013, 40(2):123-137
3. Costas Tsioufis, Iraklis Tatsis, Costas Thomopoulos, Christopher S. Wilcox, Fredrik Palm, Athanasios Kordalis, Niki Katsiki, Vasilios Papademetriou and Christodoulos Stefanadis. Effects of hypertension, diabetes mellitus, obesity and other factors on kidney hemodynamics. *Curr Vasc Pharmacol*, 2012 available online.
4. Fredrik Palm and Lina Nordquist. Diabetesnefropati. Chapter 8 in textbook "Njurmedicin", 3rd edition. Eds Aurell and Samuelsson. 2014. Liber, ISBN .
5. Peter Hansell and Fredrik Palm. A role for the extracellular matrix component hyaluronan in kidney dysfunction during ACE-inhibitor fetopathy. *Acta Physiol (Oxf)* 2015, 213(4):795-804. PMID: 25600777.
6. Leif Jansson, Andreea Barbu, Birgitta Bodin, Carl Johan Drott, Daniel Espes, Xiang Gao, Liza Grapensparr, Örjan Käallskoga, Joey Lau, Hanna Liljebäck, Fredrik Palm, My Quach, Monica Sandberg, Victoria Strömberg, Sara Ullsten and Per-Ola Carlsson. Pancreatic islet blood flow and its measurement. *Ups J Med Sci*. 2016. 28:1-15.

Dissertations

Patrik Persson "Aspects of regulation of GFR and tubular function in the diabetic kidney - Roles of adenosine, nitric oxide and oxidative stress" PhD April 2013.

Circulatory function in acute and chronic kidney injury

Michael Hultström

Cardiovascular disease is the most common cause of death. The strongest treatable risk factor for cardiovascular disease is hypertension. In patients with hypertension end-organ damage in the form of kidney failure, heart failure and vascular dysfunction is the cause of disease progression and predicts mortality driving events. Our research group focuses on interactions between the cardiovascular system and kidney function in the development of acute and chronic kidney injury using systems physiology and genome centric methods.

Kidney in hypertension

The kidneys are important in hypertension both as central regulators of blood pressure, and as one of the most important target organs for hypertensive kidney damage. We study the role of

the kidney in the development of hypertension and progression of hypertensive renal damage using physiological methods, genomics and bioinformatics.




Figure 1: Left: Renal function curves showing how C57BL/6J blood pressure increases when the animals are challenged with a high salt diet, while Balb/c can excrete the salt load without increasing blood pressure. Right: ABCC2 expression in the kidney from <http://proteinatlas.org>.

We recently found that the salt sensitive hypertension that develops (Fig 1) in C57BL/6J is associated with a mutation in ABCC2, which is also implicated in human hypertension through genome wide association studies (GWAS). Although ABCC2 is mostly known as a bile acid transporter, it is actually expressed in renal proximal tubuli, and we are working on validating its effect on blood pressure. This would be a new causal gene for human hypertension if we can validate its functional significance, like we were previously involved in for uromodulin. Beyond translating single genes we have worked with using high-level bioinformatics to translate whole groups or networks of genes. Recently, we developed a genetic network from the in-common genes in three different rat models with hypertensive kidney damage that translates surprisingly well to gene expressions in human kidney damage (Fig 2).




Figure 2: a) Gene expression changes in three hypertensive rat models with kidney damage showing 103 in-common genes. **b)** 31 in-common genes with human allograft nephropathy, and **c)** 23 with gene expression changes in elderly humans with kidney fibrosis. **d)** Genetic network of 44 highly connected genes centered around the fibronectin/complement system that also translate to human kidney damage.

Acute kidney injury

A sudden worsening of kidney function is a common and dangerous complication for example in trauma, sepsis and surgery. In the setting of chronic kidney disease an acute kidney injury (AKI) is often the precipitating event to end stage renal disease (ESRD), which is when the patient requires transplantation or dialysis to survive. We study the mechanisms behind acute cellular injury in the kidney and loss of renal function in several models focused on the role of hormonal regulation of oxygen delivery and utilisation as well as inflammatory processes and gene regulation (Fig 3).




Figure 3: Treatment with the anti hypertensive drug Losartan decreases blood pressure as expected, but it does not aggravate renal perfusion beyond than of haemorrhage in itself since it relaxes the afferent arteriole and reduces renal vascular resistance.

A major riskfactor for acute kidney injury is surgery. Up to 50% of patients fulfill the criteria for AKI after major gastrointestinal or cardiac surgery. We have addressed this question using renal gene expression in rats, either after a quick sacrifice and tissue collection, or after 3-4 hours of surgery and measurement of renal autoregulation with open abdomen. This insult in itself is enough to cause massive changes in gene expression in the kidney, and is associated with infiltration of inflammatory cells (Fig 4). This is important because it would normally be thought of as a control situation to be compared with a disease model such as haemorrhage. Perhaps the prolonged surgery actually predisposes the kidney to AKI more than many disease models in themselves.




Figure 4: Left: Heat map of over 7000 differentially expressed kidney genes after prolonged surgery. Right: PCR validation of 22 selected genes with a wide expression difference show good correlation with microarray data.

The future perspectives for our study of AKI will be to further study the effects of hormonal intervention in experimental models, but importantly to translate the findings into humans in an intervention study.

Cardiorenal syndrome

Kidney function is directly dependent on arterial pressure, and heart function on the venous filling pressure. This makes patients with combined kidney and heart failure, so called cardio-renal syndrome, particularly fragile and hard to treat. We have developed a new experimental model with a genetic difference in susceptibility to ADHF in two mouse strains (Fig 5).




Figure 5: Survival curves for the two strains. Left: C57BL/6J that show minimal morbidity and mortality, and Right: BALB/c that are more sensitive and several animals have to be sacrificed early already with only AngII treatment or high-salt diet. With the combination treatment 80% develop symptoms of heart failure within the first six days.

BALB/c mice were found to be very sensitive and most had to be sacrificed within the first six days of treatment. In contrast, C57BL/6J mice were protected. In order to better understand the genetic difference between the mouse strains we performed a genome wide mRNA expression analysis of both heart and kidney (Fig 6).




Figure 6: Differentially expressed genes between the strains during combined AngII and salt treatment in the kidney (left) and heart (right).

By comparing the the two mouse strains in the Mouse Genome Database to identify 6253 mutations, Single Nucleotide Polymorphisms (SNP), that differ between the mouse strains out of 63439 that the initial mouse diversity study focused on. This strategy identified the antioxidant system glutathion S-transferase as potentially important, which we were able to verify by investigating heart and kidney function under N-acetylcystein. Surprisingly, the higher oxidative stress in C57BL/6J seems to be a protective mechanism in the setting of fluid overload.

This project is interesting as a novel model for ADHF, and in particular since it appears to show a beneficial, or at least previously underappreciated physiological effect of oxidative stress in acute volume regulation.

Members of the group

Michael Hultström, MD, PhD, docent

Jacqueline Melville, PhD, post doc

Sofia Jönsson, PhD student

Mediha Becirovic Agic, PhD student

Di Peng, summer project student

Erik Hansi, summer project student

Annelie Barrueta, MD, residency project student

Jan Colldén, MD, Specialist in anaesthesia and intensive care, SSAI project student

Publications 2013-

41. Renal oxygenation during haemorrhage is not aggravated by Angiotensin II AT1-receptor blockade. Jacqueline M. Melville, Fredrik Palm, Michael Hultström. *Acta Physiol (Oxf)*. 2016 Feb;216(2):153-5.
42. Sympathoexcitation in Rats with Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus. Renjun Wang, Qian Huang, Zengxiang Dong, Yunfeng Qi, Hua Li, Xiaowei Wei, Hui Wu, Huiping Wang, Christopher S. Wilcox, Michael Hultström, Xiaofu Zhou, En Yin Lai. *Circulation Heart Failure*. 2016 Jan;9(1):e002261.
43. Unilateral renal ischemia in rats induces a rapid secretion of inflammatory markers to renal lymph and increased peritubular capillary permeability. Liliana Monica Bivol, Bjarne M Iversen, Michael Hultström, Paal William Wallace, Rolf K Reed, Helge Wiig, and Olav Tenstad. *J Physiol*. 2015 Nov 20. [Epub ahead of print].
44. Matrix metalloproteinase-2 knockout and heterozygote mice are protected from hydronephrosis and kidney fibrosis after unilateral ureteral obstruction. Maria K. Tveitarås, Trude Skogstrand, Sabine Leh, Frank Helle, Bjarne M. Iversen, Christos Chatziantoniou, Rolf K. Reed, Michael Hultström. *PLoS One*. 2015 Dec 16;10(12):e0143390.
45. Lack of effect of dietary nitrate in elite athletes may be due to dilation of non-prioritized vascular beds in Commentaries on Viewpoint: Can elite athletes benefit from dietary nitrate supplementation? Michael Hultström. *J Appl Physiol (1985)*. 2015 Sep 15;119(6):762-9.
46. Caloric restriction reduces age-related but not all-cause mortality. Michael Hultström. *Acta Physiol (Oxf)*. 2015 May;214(1):3-5.
47. Norepinephrine enhances angiotensin II responses via p38 MAPK activation after hypoxia/re-oxygenation in renal interlobar arteries. Jana Kaufmann, Peter Martinka, Olivia Moede, Mauricio Sendeski, Andreas Steege, Michael Fähling, Michael Hultström, Matthias Gaestel, Ivana de Moraes da Silva, Olga Zavaritskaya, Andreas Patzak. *Acta Physiol (Oxf)*. *Acta Physiol (Oxf)*. 2015 Apr;213(4):920-32.
48. Identification of a common molecular pathway in hypertensive renal damage: comparison of rat and human gene expression profiles. Trude Skogstrand, Sabine Leh, John McClure, Mohammed Dashti, Bjarne M. Iversen (deceased), Delyth Graham, Martin W. McBride, Michael Hultström. *J Hypertens*. 2015 Mar;33(3):584-96.
49. Distinct Protein Signature of Hypertension-induced Damage in the Renal Proteome of the Two-Kidney, One-Clip (2K1C) Rat Model. Heidrun Vethe, Kenneth Finne, Trude Skogstrand, Marc Vaudel, Bjørn E. Vikse, Michael Hultström, Sandrine Placier, Andreas Scherer, Olav Tenstad, Hans-Peter Marti. *J Hypertens*. 2015 Jan;33(1):126-35.
50. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Wang Z, Xu M, Hu Z, Hultström M, Lai E. *Eur J Gastroenterol Hepatol*. 2014 Sep;26(9):1015-21.

51. Renal neurohormonal regulation in heart failure decompensation. Sofia Jönsson, Mediha Becirovic Agic, Fredrik Narfström, Jacqueline M. Melville, Michael Hultström. *Am J Physiol Regul Integr Comp Physiol*. 2014 Sep;307(5):R493-R497.
52. Validation of uromodulin as a candidate gene for human essential hypertension. Lesley A Graham, Sandosh Padmanabhanm Niall J Fraser, Satish Kumar, James M Bates, Hajamohideen S Raffi, Paul Welsh, Wendy Beattie, Nicholas R Ferreri, Shoujin Hao, Sabine Leh, Michael Hultström, Anna F. Dominiczak, Delyth Graham, Martin W McBride. *Hypertension*. 2014 Mar;63(3):551-8.
53. Intradermal Insulin Delivery: A Promising Future for Diabetes Management. Hultström M, Roxhed N, Nordquist L. *J Diabetes Sci Technol*. 2014 Apr 10;8(3):453-457.
54. Prevalence and associated metabolic factors of fatty liver disease in elderly. Zhongli Wang, Ming Xu, Jianhong Peng, Li Jiang, Zhengguo Hu, Hua Wang, Shiqing Zhou, Rui Zhou, Michael Hultström, En Yin Lai. *Exp Gerontol*. 2013 Aug;48(8):705-9.
55. Nitric oxide in afferent arterioles after uninephrectomy depends on extracellular L-arginine. Helle F, Skogstrand T, Schwartz IF, Schwartz D, Iversen BM, Palm F, Hultström M. *Am J Physiol Renal Physiol*. 2013 Apr;304(8):F1088-98.
56. Neurohormonal interactions on the renal oxygen delivery and consumption in haemorrhagic shock-induced acute kidney injury. Hultström M. *Acta Physiol (Oxf)*. 2013 Sept; 209(1):11-25.
57. Arterial damage precedes the development of interstitial damage in the nonclipped kidney of two-kidney, one-clip hypertensive rats. Skogstrand T, Leh S, Paliege A, Reed RK, Vikse BE, Bachmann S, Iversen BM (late), Hultström M. *J Hypertens*. 2013 Jan;31(1):152-9.

Agencies that support the work

Swedish Society for Medical Research (SSMF)

Swedish Heart-Lung Foundation

Åke Wiberg Foundation

Magnus Bergvall Foundation

Swedish Society of Medicine

Lars Hierta Foundation

Marcus Borgström Foundation

Prizes and awards 2015

Michael Hultström: Early Career Researcher Prize, at the Neural, Hormonal and Renal Interactions in Blood Pressure Control meeting in Mussoorie, India, December 2015.

Studies of the pathophysiological mechanisms behind protein aggregation and formation of organ and cell toxic amyloid

Gunilla T Westermark

With our research we aim to pinpoint mechanisms that precede the formation of beta-cell toxic islet amyloid, and also characterize the endogenous mechanism involved in resolution of amyloid. Amyloid defines a fibrillar aggregate where beta strands of protein monomers are assembled perpendicularly to the fibrillar axis. Initiation of amyloid fibrils involves the formation of smaller intermediates, so called protofibrils that has been ascribed the cell toxic activity. Today, 30 different amyloid forming proteins have been isolated from amyloid deposits in man.


Islet amyloid and beta-cell death

The beta-cell hormone Islet Amyloid Polypeptide (IAPP) is the major amyloid component present in the islets of Langerhans in almost all individuals with type 2 diabetes. IAPP is synthesised as a larger proIAPP and arises after posttranslational processing that comprises the removal of an N-terminal and a C-terminal flanking peptide, formation of a disulfide bond and N-terminal amidation. Processing is performed by the prohormone convertases PC2 and PC1/3 and takes place in the secretory granules. Proinsulin is processed to insulin by the same convertases at the same location. ProIAPP and incomplete processed proIAPP can be detected in amyloid deposits formed in vivo, and at present we investigate how expression of PC2 and PC1/3 is affected by conditions that trigger islet amyloid formation. Mouse and rat do not develop IAPP-amyloid due to sequence variations in the IAPP molecule. Therefore, this work is performed on our human IAPP transgenic mouse strain where islet amyloid develops in male mice fed a diet high in fat for 12 months.

The transgenic hIAPP mouse model is used for studies including prevention or blocking of amyloid propagation. At present we analyse the inhibitory effect that heparin related molecules exert on amyloid formation. Also, we have established a new mouse strain that over-express heparanase and show that this reduce formation of IAPP amyloid. This work is done in collaboration with Jin-ping Li, IMBIM, UU.

Islet amyloid is also a frequent finding in transplanted islet, and we use isolated islets from the hIAPP transgenic strain and human islets from the *Nordic Network* for clinical islet transplantation to investigate if IAPP amyloidogenesis is influenced by the transplantation local. We have shown that amyloid develops to the same degree in grafts implanted under the kidney or spleen capsule or to the liver. Other locations are under investigation.

Fibrils formed from different amyloid precursor proteins appear to be morphologically inseparable. Therefore, it is possible that fibrils formed by one protein can seed amyloid made up by a second amyloid protein. We have seeded islet amyloid in human IAPP transgenic mice through administration of preformed fibrils made up by A β protein. A β and IAPP exhibits 50% sequence identity and using a high sensitive detection method, proximity ligation assay (PLA) we have identified IAPP in the brain of patients with Alzheimer's disease. The finding is interesting because type 2 diabetes increases the risk of developing Alzheimer's disease. At present, in collaboration with dr Martin Ingelsson, Uppsala and Bradley Hyman, and colleagues at Alzheimer Disease Research Center at Harvard Medical School, Massachusetts we compare amyloid plaque composition in AD patients with and without type 2 diabetes.




Western blot analysis of brain extract from an AD patient with IAPP antiserum shows a ladder like pattern. PLA performed with a combination of IAPP and A β antibodies identifies IAPP reactivity throughout the A β -paquet.

We have established a new model in *Drosophila melanogaster* for studies of proIAPP/IAPP amyloid formation. In transgenic flies expression of human proIAPP or IAPP amyloid is detected already in 20 days old flies. As expected, amyloid does not develop in control flies expressing non-amyloid-forming mouse IAPP.

The *Drosophila melanogaster* system is used for pinpointing the intracellular events that result in amyloid-linked cell death. We analyse important pathways such as ER-stress, ERAD and autophagy.

Insulin is in vitro a potent inhibitor of IAPP-aggregation and the two peptides co-localize in the secretory granules where they undergo enzymatic processing. A disturbance in cleavage and/or folding in any of the precursors might initiate amyloid aggregation. We use the *Drosophila* model to investigate if induction of human proinsulin or any of its processing metabolites in flies expressing the amyloidogenic proIAPP or IAPP will prevent amyloid formation.

The *Drosophila melanogaster* will also be used as a tool for analysis of amyloid inhibitors.




A human islet stained for amyloid by Congo red. The amyloid deposits replace most of the beta-cells. The section is viewed at 546 nm. The electron micrograph shows the border between a beta-cell and extracellular amyloid. Note the close association between the amyloid bundles and the cell membrane.

We have identified autophagy as an important mechanism that link amyloid and cell death. In collaboration with Annica Rönnbeck, KI is autophagy's role in neuronal cell death explored. This work is performed using A β -transgenic mice, human brain tissue and A β transgenic flies

There is a well-established mouse model for reactive amyloidosis (AA-amyloidosis) where N-terminal fragments (protein AA) of serum amyloid A (SAA) deposit as amyloid. We have used this model and studied resolution of amyloid. This process depends on formation of AA reactive antibodies and activation of macrophages.

We have also used this model to study transmission of amyloid and have recently shown that monocytes from a diseased mouse can prime for the disease in a recipient animal. This result points to a prion-like mechanism for spreading of amyloid. With the model, we have also shown that non-amyloid fibrillar structures can prime for AA-amyloidosis. This finding is interesting and points to a possible environmental component in the pathogenesis of the disease. To reduce the numbers of mice used for our transmission studies we explore the possibility to establish a model for AA amyloidosis in *C. elegans*. This work is ongoing and we have now transgenic worms that express human protein AA, and in these develops amyloid. Feeding worms on OP50 bacteria mixed with amyloid fibrils leads to disturbance in mobility and is indicative for transmission.



The transgenic *C. elegans* express GFP and an amyloid protein (e.g. AA 45). The expression is driven to the body wall muscle. The presence of the green GFP allows us to monitor the movements of the worm. Aged worms, for amyloid with Congo red exert green birefringence when viewed in polarised light.

Members of the group

Gunilla T Westermark, PI

Lakshim Kotegala, Post Doc

Camilla Krappe, Post Doc

Marie Oskarsson, PhD Student

Gu Xiaohong, PhD Student

Ye Wang, Ph.D. Student

Marianne Ljungkvist, Laboratory engineer

Agencies that support the work

The Swedish Research Council

The Swedish Diabetes Association

Family Ernfors Foundation

Alzheimer fonden

Novo Nordisk

Gamla Tjänarinnor

You've Got Mail: Message Delivery Within and Between Cells

Johan Kreuger

The main goal of our research program is to address the question of how messages and packages are sent to the right addresses within and between cells in our bodies. This is a fundamental question. It is very important for the around 100,000 billion cells in the human body to communicate, in order to collaborate and sustain life. Malfunctioning package delivery in this context may lead to inappropriate cell behaviour, and in the worst case to disease such as cancer. We are particularly interested in cellular packages and messages that direct the collective movements of cell clusters. Cells move together during normal development and wound healing, but also during cancer progression.

The main project family in our lab deals with the roles of the exocyst complex in the recruitment of intracellular vesicles to the plasma membrane. Proteins of the exocyst complex

are attached to vesicles containing information (i.e. different molecules) that move using motorproteins along cytoskeletal highways in the cell en route to their final destinations. At the final destination (the target membrane) other exocyst components are awaiting, and binding between vesicle-bound and membrane-bound exocyst proteins leads to vesicle tethering. The tethering step is then followed by fusion of the vesicle with the plasma membrane resulting in release of vesicular cargo. Importantly, components of the exocyst undergo alternative splicing, yielding a variety of isoforms, some of which have been associated with distinct cellular behaviors such as epithelial-mesenchymal transition and migration/invasion. The different exocyst protein isoforms are probably central to how vesicles can be delivered to specific destinations and packages ultimately released in a controlled manner. We are interested in the structural and functional implications of alternative splice variants, both with respect to interactivity between exocyst components and their potential for context-specific expression. Another long-term ambition is to better understand how the molecular machineries regulating assembly and delivery of intracellular and extracellular packages originated and evolved after that life emerged on Earth some 4 billion years ago.

Most projects in the lab employ a variety of molecular biology tools (e.g. qPCR, RNAi, cloning, overexpression of tagged proteins) to study transcript splicing and to perform loss- and gain-of-function experiments, as well as microscopy techniques (including confocal and TIRF) to study exocyst and vesicle trafficking events required for proper cell behavior and cell migration. We study exocyst function in cancer cells, epithelial cells and endothelial cells. We use biochemical approaches to study protein-protein and protein-drug interactions, and microfluidic assays to study cell migration.

Several projects in the lab involve the construction of new methods for detailed studies of cell communication and collective cell migration. Previous projects in the lab have resulted in patents and industrial applications and in the formation of the spin-off company Gradientech AB.

Publications 2013-

1. Filipek-Górniok, B., Holmborn, K., Haitina, T., Habicher, J., Oliveira, M., Hellgren, C., Eriksson, I., Kjellén, L., Kreuger, J., Ledin, J. (2013) Expression of chondroitin/dermatan sulfate glycosyltransferases during early zebrafish development.

Developmental Dynamics, 242(8):964-75.

2. Kasza Z, Fuchs PF, Tamm C, Eriksson AS, O'Callaghan P, Heindryckx F, Spillmann D, Larsson E, Le Jan S, Eriksson I, Gerwins P, Kjellen L, Kreuger J. (2013) MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to VEGFA.

J Biol Chem. 288(36):25956-63.

3. Hua Huang, Elise Langenkamp, Maria Georganaki, Angelica Loskog, Peder Fredlund Fuchs, Lothar C. Dieterich, Johan Kreuger, Anna Dimberg, (2014) VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kB-induced endothelial activation

FASEB J. 29(1):227-38.

4. Sara Massena, Gustaf Christoffersson, Evelina Vågesjö, Cédric Seignez, Karin Gustafsson, Francois Binet, Carmen Herrera Hidalgo, Antoine Giraud, Jalal Lomei, Simone Weström, Masabumi Shibuya, Lena Claesson-Welsh, Pär Gerwins, Michael Welsh, Johan Kreuger, and Mia Phillipson (2015) Identification and characterization of VEGF-A-responsive neutrophils expressing VEGFR1, CD49d and CXCR4 in mice and humans
Blood 126(17):2016-26

5. Kreuger J, Phillipson M. (2015) Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.
Nature Reviews Drug Discovery 15(2):125-42.

6. Heindryckx F, Binet F, Ponticos M, Rombouts K, Lau J, Kreuger J*, Gerwins P* (2016) Endoplasmic reticulum stress enhances fibrosis through IRE1a-mediated degradation of miR-150 and XBP-1 splicing
EMBO Molecular Medicine, in press

Members of the group

Johan Kreuger, senior lecturer

Paul O'Callaghan, postdoc

Rodrigo Hernández Vera, postdoc

Nikos Kavalopoulos, PhD student

Parham Ashrafzadeh, PhD student

Carl Andrén Lundahl, project student

Agencies that support the group

Swedish Cancer Society (JK)

The Marie Skłodowska-Curie Innovative Training Network InCeM (JK)

Alzheimerfonden (POC)

Demensförbundet (POC)

Astrid Karlssons Stiftelse (RHV)

Publications 2013-

- 1: Oskarsson ME, Singh K, Wang J, Vlodavsky I, Li JP, Westermark GT. Heparan Sulfate Proteoglycans Are Important for Islet Amyloid Formation and Islet Amyloid Polypeptide-induced Apoptosis. J Biol Chem. 290:15121-15132, 2015

- 2: Westermark GT, Oskarsson M, Andersson A, Westermark P. Eighty years of research on islet amyloidosis in Uppsala. Ups J Med Sci. 120:117-123, 2015

- 3: Oskarsson ME, Paulsson JF, Schultz SW, Ingelsson M, Westermark P, Westermark GT. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. *Am J Pathol.* 185:834-846, 2015
- 4: Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. *Annu Rev Pathol.* 10:321-344, 2015 Review
5. Hermansson E, Schultz SW, Crowther D, Linse S, Winblad B, Westermark GT, Johansson J, Presto J. The chaperone domain BRICHOS prevents CNS toxicity of amyloid- β peptide in *Drosophila melanogaster*. *Dis Model Mech.* 7:659-65, 2014
- 6: Paulsson JF, Ludvigsson J, Carlsson A, Casas R, Forsander G, Ivarsson SA, Kockum I, Lernmark Å, Marcus C, Lindblad B, Westermark GT. High plasma levels of islet amyloid polypeptide in young with new-onset of type 1 diabetes mellitus. *PLoS One*;9(3):e93053, 2014
- 7: Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. *Ups J Med Sci.* 119:223-228, 2014
- 8: Caballero F, Siniakowicz K, Hollister-Lock J, Duran L, Katsuta H, Yamada T, Lei J, Deng S, Westermark GT, Markmann J, Bonner-Weir S, Weir GC. Birth and death of human β -cells in pancreases from cadaver donors, autopsies, surgical specimens, and islets transplanted into mice. *Cell Transplant.* 23:139-151, 2014
- 9: Lundmark K, Vahdat Shariatpanahi A, Westermark GT. Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis. *PLoS One.* 13;8:e79104. 2013
- 10: Westermark GT, Westermark P. Islet amyloid polypeptide and diabetes. *Curr Protein Pept Sci.* 14:330-337. 2013 Review.
- 11: Sponarova J, Nuvolone M, Whicher C, Frei N, Kana V, Schwarz P, Westermark GT, Aguzzi A. Efficient amyloid A clearance in the absence of immunoglobulins and complement factors. *Am J Pathol.* 182:1297-1307, 2013

Dissertations

Oskarsson, Marie. Islet amyloid polypeptide (IAPP) in Type 2 diabetes and Alzheimer disease. Diss. Uppsala Universitet.

Dissertations 2015

- **Gandasi, Nikhil R.** (2015) Molecular mechanisms of biphasic insulin secretion. Diss. Uppsala Universitet.
- **Massena, Sara.** (2015) A close-up on neutrophils: Visualizing the mechanisms of their in vivo recruitment and function. Diss. Uppsala Universitet.
- **Oskarsson, Marie.** (2015) Islet amyloid polypeptide (IAPP) in Type 2 diabetes and Alzheimer disease. Diss. Uppsala Universitet.

Licentiate theses 2015

Alenkvist, I

Ashrafzadeh, P

Cen, J

Grapensparr, L

Kristinson, H

Liu, C

Singh, K

Sivertsson, E

Ullsten, S

Economy

(kSEK)

	2014	2015
Undergraduate Education appropriations	33 510	34 273
Faculty appropriations	20 671	20 921
External Grants	37 620	40 415
Contract research	1 082	180
Total	92 883	95 789

Undergraduate Teaching

The department participates in 7 different study programmes (utbildningsprogram): medicine, pharmacy, biomedicine (Bachelor and Master programmes), nursing, biomedical laboratory science and dieticians and dispensers. In addition, it hosts a number of single subject courses (fristående kurser). Some 1500 students per year are given education at the department. The courses given by MCB generally get very good gradings in the course evaluations by the students.

Medicine

The department contributes teaching in anatomy, cell biology and physiology with both traditional lectures and problem based learning as well as with seminars and laboratory experiments. Most of this teaching is given during terms 1-3 of the programme but extensive parts are also given in the later integrated courses. The overall objective is to provide basic knowledge of the morphology and function of the human body and to create a basis for the following clinical studies. Some 115 students are enrolled every semester.

Biomedicine

This three-year Bachelor programme aims to give students a thorough understanding of normal morphology and function of the human body. The programme is given annually and provides the students training for future activity in research, information and education. The department takes part in the teaching of anatomy, embryology, cell biology and physiology. About 40 students are enrolled each year.

The two-year Master programme in Biomedicine is an international programme that aims to give a deeper knowledge in the subjects taught in the Bachelor's programme, and also offers the students an opportunity to specialize in their field of interest. The department gives the first course in the programme, Major Diseases - Homeostasis and Endocrine Disorders. The programme enrolls approximately 30 students annually.

Pharmacy

The department is responsible for the teaching in anatomy and physiology for the University Diploma of Pharmacy. The courses are in the form of lectures, seminars and laboratory experiments. Some 140 students are enrolled every semester.

Clinical dieticians

The anatomy and physiology course included in the programme for clinical dieticians is given annually by the department, and include lectures, seminars and laboratory experiments for approximately 30 students.

Nursing sciences

The department is responsible for the teaching of anatomy, cell biology and physiology in the form of lectures and seminars. Some laboratory experiments are involved as well. Some 130

students are enrolled in the spring semester and 150 students are enrolled in the autumn semester. Thus approximately 280 students are enrolled every year. A new responsibility since 2014 is the education of nurses on Gotland where MCB through data link lecture for the students in the above subjects just as for our students in Uppsala. Approximately 40 students are enrolled every year.

Biomedical laboratory sciences

The aim of this programme is to produce technicians with appropriate training for a future task in diagnostic and research laboratories. The department is responsible for the teaching in anatomy, histology, cell biology and physiology in the form of lectures, seminars and laboratory experiments. Some 35 students are enrolled each year

Medical student assistants

Three medical students are enrolled for a period of 3 year during which they teach younger medical students and participate in research.

Single subject courses (fristående kurser)

Anatomy A (evening course)

Transplantation biology (evening course)

Cell biology I and II (evening course)

Medical cell biology (laboratory project course)

Histology

Physiology

Basic medical physiology

Summer research school (SOFOSKO)

Major Diseases - Homeostasis and endocrine disorders

Graduate Teaching

The department has the responsibility for two of the Mandatory Courses for Graduate Students Introduction to Scientific Research – enrolling 80 Graduate students per year and Scientific Presentation – enrolling 40-50 Graduate students per year.

MD/PhD programme

MCB is responsible for the administration and content of the MD/PhD programme. The Medical Faculty and Upsala Society of Physicians provide grants for three undergraduate medical studies per year to join the MD/PhD programme. These students pursue medical undergraduate studies in parallel with a graduate research project. After finishing medical studies the MD/PhD students have a period of full-time research leading to half-time or Licentiate exam. Students then continue with internship combined with continued graduate research project studies. After obtaining the MD a full-time research period leads to the PhD.

Centres and Facilities

Advanced light microscopic imaging facilities

Within the department there are several advanced setups for fluorescence imaging of living cells and micro-organs. These setups are based on bright field microscopy, conventional fluorescence microscopy, epifluorescence microscopy, total internal reflection fluorescence (TIRF) microscopy and confocal microscopy. We also have a laser capture microscope.

Fluorescence and intra-vital microscopy

Fluorescence imaging using epifluorescence is used for on-line monitoring of the cytoplasmic Ca^{2+} concentration in superfused islets of Langerhans and dispersed islet cells (Anders Tengholm, 018 471 4481). Similar studies of Ca^{2+} , nitric oxide and oxygen radicals are performed on single perfused kidney glomeruli and the juxtaglomerular apparatus (Erik Persson, 018 471 4180) and interactions between leukocytes and endothelial cells leading to leukocyte transmigration and vessel permeability are studied in the adipose tissue, gastrointestinal tract and skeletal muscle in vivo (Lena Holm, 018 4714325, Mia Phillipson, 018 471 4419). Membrane order is studied in live cells by ratiometric imaging in combination with deconvolution (Ingela Parmryd, 018 471 41 50).

TIRF microscopy

The department possesses 6 TIRF (or evanescent wave) microscopes, two of which are custom-built systems with prism-type configuration and 4 using custom-built or commercial through-the-lens illumination. The systems are differently equipped with gas and diode-pumped solid-state lasers to provide excitation at multiple lines, including 405, 442, 457, 488, 514 and 561 nm. These setups are used for on-line monitoring of cAMP, cytoplasmic Ca^{2+} , IP_3 , DAG, PIP_2 , PIP_3 and other signalling molecules using indicators based on different spectral variants of green fluorescent protein (Anders Tengholm, 018 471 4481) and imaging of single molecules involved in exocytosis of secretory vesicles (Sebastian Barg, 018 471 4660).

PALM and STORM superresolution microscopy

One of the multicolour TIRF microscopes is equipped for stochastic superresolution microscopy in live and fixed cells. Fluorescently labeled proteins (eg. GFP fusion proteins or antibody labelling) can be localized with a resolution of 20-50 nm. (Sebastian Barg, 018 471 4660).

Confocal microscopy

The laboratory has three inverted confocal microscopes, one fast spinning disc (Nipkow) system used for studies of living islets of Langerhans and dispersed islet cells (Anders Tengholm, 018 471 4481), one scanning confocal system mostly used for structural studies (Nils Welsh, 018 471 4212), one advanced state-of-the-art system suitable for live cell imaging (Oleg Dyachok, 018 471 4345) and an upright high speed confocal microscope for in vivo studies (Zeiss LSM5 Live, Mia Phillipson, 018 471 4419).

Laser capture microscopy

The department has a laser capture microscope (LMD6000, Leica) that can be used to isolated cells or other regions of interest from sectioned tissues for further analysis. Depending on internal use, this equipment is available for external users on a charged service basis (Per-Ola Carlsson, 018 471 4425, Sara Ullsten, 018 471 4395).

Gel imaging

The department has a LI-COR Odyssey FC and a Kodak 4000MM gel imaging unit (Nils Welsh, 018 471 4212) and a Bio-Rad Fluor-S MultiImager system for scanning and quantification of proteins in gels and membranes (Peter Bergsten, 018 471 4923).

Digital cameras

Several of the imaging systems are equipped with ultra-sensitive state of the art cameras, some utilizing back-thinned electron multiplying charge coupled device (EMCCD) technique.

Other equipment

Real-time PCR (Roche Lightcycler, Nils Welsh, 018 471 4212).

Flow cytometry and cell sorting (BD FacsCalibur, Nils Welsh, 018 471 4212).

Laser Doppler blood flow measurement equipment (Lena Holm, 018 471 4325).

Patch clamp equipment for electrophysiological recordings (Sebastian Barg, 018 471 4660).

Fluoroscan supplied with detectors for luminescence and absorbance (Gunilla Westermark, 018 471 4169).

Nanodrop for DNA/RNA and protein quantification (Gunilla Westermark, 018 471 4169).

Mesoscale multiplex immunoassays (Erik Gylfe, 018, 471 4428)

EPR (electron paramagnetic resonance) for measuring free radicals (Fredrik Palm, 018 471 4182).

EnSpire Alpha Plate Reader, Perkin Elmer (Anders Tengholm, 018 471 4481)

Small animal ultrasound (Vevo 1100) with 1000 Hz time-resolution and 30µm spatial resolution for functional cardiovascular imaging in rats and mice. (Michael Hultström 0707648454)

Cardiac output monitor for patients (LiDCO) that uses pulse-wave analysis to estimate cardiac output with a lithium-dilution calibration during surgery or critical care. (Dept. Surg. Sci. Michael Hultström 0707648454)

LI-COR Odyssey FC gel scanner (Nils Welsh, 018 4714212).

Prizes and awards 2015

Kailash Singh: the Young Investigators Award from Scandinavian Society for the Study of Diabetes

Evelina Vågesjö: SKAPA framtidens innovatör i Uppland, UIC Business Lab vinnare av fiktiva investeringar från juryn

Per-Ola Carlsson: The Knud Lundbeck Award from the Scandinavian Society for the Study of Diabetes

Nikhil Gandasi: European Foundation for the Study of Diabetes (EFSD) / Lilly Research Fellowship

Nikhil Gandasi: a two-year research fellowship från Svenska Sällskapet för Medicinsk Forskning (SSMF).

Michael Hultström: the early Career Researcher Prize, at the Neural, Hormonal and Renal Interactions in Blood Pressure Control meeting in Mussoorie, India, December 2015.

Mia Phillipson: elected member of the Swedish Young Academy (Sveriges unga akademi).

Marie E. Oskarsson's PhD theses "*Islet amyloid polypeptide (IAPP) in Type 2 diabetes and Alzheimer disease*" has been recognized by the Swedish Society of Diabetology (SFD) as the best preclinical dissertation in 2015.

E-mail address list

Department of Medical Cell Biology

www.mcb.uu.se

Address: Uppsala University, Biomedical Center, Box 571, 751 23 Uppsala, Sweden

Office: Fax +46 18 471 4059, Phone +46 18 471 4328, +46 18 471 4431

- **Adler, Jeremy** research engineer
- **Ahl, David** doctoral student david.ahl@mcb.uu.se
- **Ahooghalandari, Parvin** research engineer, +46 18 4714924
parvin.ahooghalandari@mcb.uu.se research engineer +46 18 4714924
- **Al-Mashhadi, Ammar Nadhom Farman** guest doctoral student
- **Alenkvist, Ida** assistant undergoing research training ida.alenkvist@mcb.uu.se
- **Aluthgedara, Warunika** research assistant, warunika.aluthgedara@mcb.uu.se
- **Andersson, Arne** professor emeritus, +46 18 4714397
arne.andersson@mcb.uu.se
- **Arbrandt, Gustav** doctoral student gustav.arbrandt@mcb.uu.se
- **Ashrafzadeh, Parham** doctoral student parham.ashrafzadeh@mcb.uu.se
- **Azarbayjani, Faranak** lecturer, +46 18 4714450 faranak.azarbayjani@mcb.uu.se
- **Barbu, Andreea** researcher, +46 18 4714316 andreea.barbu@mcb.uu.se
- **Barg, Sebastian** researcher, +46 18 4714660 sebastian.barg@mcb.uu.se
- **Barrueta, Annelie** degree project worker annelie.barrueta@mcb.uu.se
- **Becirovic Agic, Mediha** doctoral student mediha.agic@mcb.uu.se
- **Bergsten, Peter** professor +46 18 4714923 professor, +46 18 4714923

- peter.bergsten@mcb.uu.se
- **Blixt, Martin** lecturer, +46 18 4715005 martin.blixt@mcb.uu.se
 - **Bodin, Birgitta** research engineer birgitta.bodin@mcb.uu.se
 - **Bodén, Christofer** stipendiat
 - **Bohman, Sara** lecturer, +46 18 4715005 sara.bohman@mcb.uu.se
 - **Boqvist, Nathalie** degree project worker
 - **Borg, Håkan** senior lecturer, +46 18 4714353 hakan.borg@mcb.uu.se
 - **Börjesson, Joey Lau** researcher joey.lau@mcb.uu.se
 - **Caballero-Corbalan, José** visiting researcher
 - **Carlsson, Per-Ola** professor, +46 18 4714425 per-ola.carlsson@mcb.uu.se
 - **Carlström, Mattias** researcher mattias.carlstrom@mcb.uu.se
 - **Carvalho, Carla** doctoral student carla.carvalho@mcb.uu.se
 - **Cen, Jing** doctoral student jing.cen@mcb.uu.se
 - **Chowdhury, Azazul Islam** doctoral student, +46 18 4714427
azazul.chowdhury@mcb.uu.se
 - **Christensen, Michael** doctoral student michael.christensen@mcb.uu.se
 - **Christoffersson, Gustaf** post doctoral gustaf.christoffersson@mcb.uu.se
 - **Ciba, Iris** physician
 - **Dahlbom, Marie** research nurse
 - **Dansk, Heléne** research engineer +46 18 4714924 research engineer, +46 18 4714924 helene.dansk@mcb.uu.se
 - **Drott, Carl Johan** doctoral student carljohan.drott@mcb.uu.se
 - **Drzazga, Anna** guest doctoral student
 - **Dyachok, Oleg** senior research engineer, +46 18 4714345
oleg.dyachok@mcb.uu.se
 - **Eckerbom, Per** consultant
 - **Ejdesjö, Andreas** post doctoral andreas.ejdesjo@mcb.uu.se
 - **Elhorst, Paula** degree project worker
 - **Elksnis, Andris** teaching assistant
 - **Engberg, Adam** degree project worker
 - **Enström, Emma** degree project worker
 - **Eriksson, Olle** degree project worker
 - **Eriksson, Ulf** professor, +46 18 4714129 ulf.eriksson@mcb.uu.se
 - **Espes, Daniel** doctoral student, +46 18 4714397 daniel.espes@mcb.uu.se
 - **Fasching, Angelica** research engineer, +46 18 4714156
angelica.fasching@mcb.uu.se research engineer, +46 18 4714156
angelica.fasching@mcb.uu.se
 - **Flacker, Peter** visiting researcher peter.flacker@mcb.uu.se
 - **Forslund, Anders** researcher
 - **Franzén, Petra** laboratory technician petra.franzen@mcb.uu.se
 - **Fred, Rikard** post doctoral rikard.fred@mcb.uu.se
 - **Friederich Persson, Malou** researcher, +46 18 4714184
malou.friederich@mcb.uu.se
 - **Gaifém, Francisca** degree administration officer
 - **Gandasi, Nikhil** researcher nikhil.gandasi@mcb.uu.se
 - **Gao, Xiang** post doctoral, +46 18 4714183 gao.xiang@mcb.uu.se post doctoral
+46 18 4714183 gao.xiang@mcb.uu.se
 - **Germain, Kyla** visiting student
 - **Gerwins, Pär** professor, specialist physician, +46 18 4714079
par.gerwins@mcb.uu.se
 - **Giraud, Antoine** research engineer, +46 18 4714324 antoine.giraud@mcb.uu.se
 - **Grapengiesser, Eva** researcher +46 18 4714424 researcher, +46 18 4714424
eva.grapengiesser@mcb.uu.se
 - **Grapensparr, Liza** doctoral student, +46 18 4714460

- liza.grapensparr@mcb.uu.se
- **Gu, Xiaohong** doctoral student, +46 18 4714292 xiaohong.gu@mcb.uu.se
 - **Gucek, Alenka** post doctoral alenka.gucek@mcb.uu.se
 - **Gylfe, Erik** professor emeritus, +46 18 4714428 professor emeritus, +46 18 4714428 erik.gylfe@mcb.uu.se
 - **Hallgren, Ing-Britt** research engineer ing-britt.hallgren@mcb.uu.se
 - **Hansell, Peter** professor, +46 18 4714130 peter.hansell@mcb.uu.se professor, +46 18 4714130 peter.hansell@mcb.uu.se
 - **Heindryckx, Femke** post doctoral, +46 18 4714184 femke.heindryckx@mcb.uu.se
 - **Hellman, Bo** professor emeritus +46 18 4714424 professor, +46 18 4714424 bo.hellman@mcb.uu.se
 - **Herrera Hidalgo, Carmen** doctoral student carmen.herrerahidalgo@mcb.uu.se
 - **Hirt, Christian** degree project worker
 - **Hjort, Marcus** teaching assistant
 - **Hjortberg, Mats** senior lecturer, +46 18 4714269 mats.hjortberg@mcb.uu.se
 - **Holm, Lena** professor, +46 18 4714325 lena.holm@mcb.uu.se
 - **Holmfeldt, Per** lecturer per.holmfeldt@mcb.uu.se
 - **Hultström, Michael** researcher, +46 18 4714460 michael.hultstrom@mcb.uu.se
 - **Idevall, Olof** postdoctoral research fellow olof.idevall@mcb.uu.se
 - **Ishtiaq, Ali** degree project worker
 - **Islam, Nikita** degree project worker
 - **Jamalpournobijari, Maria** doctoral student maria.jamalpour@mcb.uu.se
 - **Jansson, Leif** professor, +46 18 4714396 leif.jansson@mcb.uu.se
 - **Jägare, Annika** laboratory technician, +46 18 4714324 annika.jagare@mcb.uu.se
 - **Jönsson, Sofia** doctoral student sofia.jonsson@mcb.uu.se
 - **Karlsson, Susanne** research engineer susanne.karlsson@mcb.uu.se
 - **Kavalopoulos, Nikos** doctoral student nikos.kavalopoulos@mcb.uu.se
 - **Kay, Emma** researcher emma.kay@mcb.uu.se
 - **Knowles, Michelle Kay** researcher michelle.knowles@mcb.uu.se
 - **Kothegala, Lakshmi** post doctoral lakshmi.kothegala@mcb.uu.se
 - **Kreuger, Johan** degree project worker
 - **Kreuger, Johan** senior lecturer, +46 18 4714079 johan.kreuger@mcb.uu.se
 - **Kristinsson, Hjalti** doctoral student hjalti.kristinsson@mcb.uu.se
 - **Krizhanovskii, Camilla** post doctoral, +46 18 4714925 camilla.krizhanovskii@mcb.uu.se
 - **Kullman, Lisen** researcher (LOA), +46 18 4714345 lisen.kullman@mcb.uu.se
 - **Källskog, Örjan** professor emeritus orjan.kallskog@mcb.uu.se
 - **Li, Jia** doctoral student jia.li@mcb.uu.se
 - **Li, Xiujuan** post doctoral xiujuan.li@mcb.uu.se
 - **Li, Zhanchun** senior research engineer zhanchun.li@mcb.uu.se
 - **Liljebäck, Hanna** teaching assistant hanna.liljeback@mcb.uu.se
 - **Lindfors, Lina** guest doctoral student
 - **Liss, Per** docent, consultant
 - **Liu, Chenxiao** doctoral student chenxiao.liu@mcb.uu.se
 - **Liu, Haoyu** post doctoral haoyu.liu@mcb.uu.se
 - **Ljung, Leif** senior research engineer leif.ljung@mcb.uu.se
 - **Ljungkvist, Marianne** research engineer marianne.ljungkvist@mcb.uu.se
 - **Lomei, Jalal** doctoral student, +46 18 4714319 jalal.lomei@mcb.uu.se
 - **Lund, Per-Eric** senior research engineer per-eric.lund@mcb.uu.se
 - **Lundin, Sara** degree project worker
 - **Lundström, Carl** personnel administrator, +46 18 4714431 carl.lundstrom@mcb.uu.se
 - **Magnusson, Louise** doctoral student louise.magnusson@mcb.uu.se

- **Manell, Hannes** doctoral student hannes.manell@mcb.uu.se
- **Marshall, Misty** post doctoral misty.marshall@mcb.uu.se
- **Massena, Sara** researcher, +46 18 4714319 sara.massena@mcb.uu.se
- **Melville, Jacqueline Mary** post doctoral jacqueline.melville@mcb.uu.se
- **Morshed, Mohammed Monzur** degree project worker
- **Müllner, Elisabeth** visiting researcher
- **Nakato, Hiroshi** visiting researcher
- **Nehlbäck, Edward** teaching assistant
- **Nensén, Oskar** teaching assistant oskar.nensen@mcb.uu.se
- **Nguyen, Phuoc My** doctoral student my.nguyen@mcb.uu.se
- **Niklasson, Bo** adjunct professor bo.niklasson@mcb.uu.se
- **Nilsson, Gunno** research engineer gunno.nilsson@mcb.uu.se
- **Nilsson, Ove** professor emeritus ove.nilsson@mcb.uu.se
- **Nordin, Astrid** research engineer, +46 18 4714395 astrid.nordin@mcb.uu.se
- **Nordquist, Lina** postdoctoral research fellow lina.nordquist@mcb.uu.se
- **Omar Hmeadi, Muhmmad** doctoral student omar.hmeadi@mcb.uu.se
- **Oskarsson, Marie** doctoral student, +46 18 4714967
marie.oskarsson@mcb.uu.se
- **O'Callaghan, Paul** researcher, +46 18 4714184 paul.ocallaghan@mcb.uu.se
- **Palm, Fredrik** professor, +46 18 4714182 fredrik.palm@mcb.uu.se
- **Pan, Shumin** finance officer, +46 18 4714328 shumin.pan@mcb.uu.se
- **Parekh, Vishal** post doctoral vishal.parekh@mcb.uu.se
- **Parmryd, Ingela** researcher, +46 18 4714150 ingela.parmryd@mcb.uu.se
- **Persson, Elis** degree project worker
- **Persson, Erik** professor, +46 18 4714180 erik.persson@mcb.uu.se
- **Persson, Patrik** post doctoral, +46 18 4714156 patrik.persson@mcb.uu.se
- **Phillipson, Mia** professor, +46 18 4714419 mia.phillipson@mcb.uu.se
- **Quach, My** senior research engineer, +46 18 4714183 my.quach@mcb.uu.se
- **Raman, Ratish** project assistant
- **Rojas Vazquez, Ismael** degree project worker
- **Runesson, Klara** course administrator, +46 18 4714414,
klara.runesson@mcb.uu.se
- **Rydgren, Tobias** post doctoral tobias.rydgren@mcb.uu.se
- **Sagulin, Lisbeth** research engineer, +46 18 4714395 lisbeth.sagulin@mcb.uu.se
- **Sandberg, Monica** senior research engineer, +46 18 4714440
monica.sandberg@mcb.uu.se
- **Sandin, Erik** course administrator, +46 18 4714414
erik.sandin@mcb.uu.se course administrator +46 18 4714414
- **Sandler, Stellan** professor, +46 18 4714430 stellan.sandler@mcb.uu.se
- **Saras, Jan** research engineer +46 18 4714967 jan.saras@mcb.uu.se
- **Sargsyan, Ernest** researcher, +46 18 4714427 ernest.sargsyan@mcb.uu.se
- **Schiffer, Tomas** post doctoral tomas.schiffer@mcb.uu.se
- **Sedin, John** researcher, +46 18 4714319 john.sedin@mcb.uu.se
- **Seignez, Cedric** post doctoral, +46 18 4714409 cedric.seignez@mcb.uu.se
- **Shuai, Hongyan** doctoral student hongyan.shuai@mcb.uu.se
- **Singh, Kailash** doctoral student, +46 18 4714411 kailash.singh@mcb.uu.se
- **Sivertsson, Ebba** teaching assistant, +46 18 4714378
ebba.sivertsson@mcb.uu.se
- **Soläng, Charlotte** degree project worker
- **Spaak, Johanna** visiting researcher
- **Sparby, Jakob** guest doctoral student
- **Staaf, Johan** doctoral student johan.staaf@mcb.uu.se
- **Strömberg, Victoria** stipendiat
- **Ståhl, Göran** department technician, +46 18 4714153 goran.stahl@mcb.uu.se

- **Tengholm, Anders** professor, +46 18 4714481
anders.tengholm@mcb.uu.se professor +46 18 4714481
- **Thonig, Antje** laboratory technician antje.thonig@mcb.uu.se laboratory technician
- **Thorvaldson, Lina** course administrator +46 18 4714216 course administrator,
+46 18 4714216 lina.thorvaldson@mcb.uu.se lecturer +46 18 4714216
- **Törnelius, Eva** laboratory technician eva.tornelius@mcb.uu.se
- **Ullsten, Sara** doctoral student, +46 18 4714292 sara.ullsten@mcb.uu.se
- **Vasylovska, Svitlana** biomedical analyst svitlana.vasylovska@mcb.uu.se
- **Vera, Rodrigo Hernández** post doctoral rodrigo.hernandez@mcb.uu.se
- **Vågesjö, Evelina** doctoral student, +46 18 4714324 evelina.vagesjo@mcb.uu.se
- **Waldén, Tomas** post doctoral tomas.walden@mcb.uu.se
- **Wang, Xuan** post doctoral, +46 18 4714925 xuan.wang@mcb.uu.se
- **Wedin, Johan** project assistant
- **Welsh, Michael** professor, +46 18 4714447 michael.welsh@mcb.uu.se
- **Welsh, Nils** professor, +46 18 4714212 nils.welsh@mcb.uu.se
- **Wentzel, Parri** senior lecturer, +46 18 4714033 parri.wentzel@mcb.uu.se
- **Westermarck, Gunilla** professor, +46 18 4714169 gunilla.westermarck@mcb.uu.se
- **Widhe, Mona** visiting researcher
- **Wolgast, Mats** professor mats.wolgast@mcb.uu.se
- **Wuttke, Anne** researcher, +46 18 4714426 anne.wuttke@mcb.uu.se
- **Xie, Beichen** doctoral student beichen.xie@mcb.uu.se
- **Xu, Yunjian** senior research engineer, +46 18 4714426 yunjian.xu@mcb.uu.se
- **Yin, Peng** doctoral student peng.yin@mcb.uu.se
- **Yu, Qian** doctoral student qian.yu@mcb.uu.se
- **Zhao, Lijun** laboratory technician lijun.zhao@mcb.uu.se laboratory technician
lijun.zhao@mcb.uu.se
- **Zollbrecht, Christa** post doctoral christa.zollbrecht@mcb.uu.se
- **wang, ye** doctoral student ye.wang@mcb.uu.se
- **Åkerblom, Björn** course administrator +46 18 4714412 course administrator, +46
18 4714412 bjorn.akerblom@mcb.uu.se